<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.03.22.21253621</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Infectious Diseases (except HIV/AIDS)</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>COVID-19 therapeutics for low- and middle-income countries: a review of re-purposed candidate agents with potential for near-term use and impact</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Maxwell</surname><given-names>Daniel</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sanders</surname><given-names>Kelly C.</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sabot</surname><given-names>Oliver</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hachem</surname><given-names>Ahmad</given-names></name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Llanos-Cuentas</surname><given-names>Alejandro</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Olotu</surname><given-names>Ally</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gosling</surname><given-names>Roly</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cutrell</surname><given-names>James B.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hsiang</surname><given-names>Michelle S.</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a6">6</xref>
<xref ref-type="aff" rid="a7">7</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Department of Medicine, University of Texas (UT) Southwestern Medical Center</institution>, Dallas, <country>USA</country></aff>
<aff id="a2"><label>2</label><institution>Pandemic Response Initiative, Institute for Global Health Sciences, University of California</institution>, San Francisco (UCSF), <country>USA</country></aff>
<aff id="a3"><label>3</label><institution>Department of Pediatrics, Stanford University</institution>, Stanford, <country>USA</country></aff>
<aff id="a4"><label>4</label><institution>Institute of Tropical Medicine Alexander von Humbolt (IMTAvH), Universidad Peruana Cayetano Heredia (UPCH)</institution>, Lima, <country>Peru</country></aff>
<aff id="a5"><label>5</label><institution>Clinical Trials and Interventions Unit, Ifakara Health Institute</institution>, Bagamoyo, <country>Tanzania</country></aff>
<aff id="a6"><label>6</label><institution>Department of Pediatrics, UT Southwestern Medical Center</institution>, Dallas, <country>USA</country></aff>
<aff id="a7"><label>7</label><institution>Department of Pediatrics</institution>, UCSF</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Correspondence to: Michelle Hsiang, MD MSc, Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, USA <email>michelle.hsiang@utsouthwestern.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.03.22.21253621</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>3</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>22</day>
<month>3</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>3</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="21253621.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>Low- and middle-income countries (LMICs) face significant challenges in the control of COVID-19, given limited resources, especially for inpatient care. In a parallel effort to that for vaccines, the identification of therapeutics that have near-term potential to be available and easily administered is critical. Using the United States, European Union, and World Health Organization clinical trial registries, we reviewed COVID-19 therapeutic agents currently under investigation. The search was limited to oral or potentially oral agents, with at least a putative anti-SARS-CoV-2 virus mechanism, and with at least 3 registered trials. We describe the available evidence regarding agents that met these criteria and additionally discuss the need for additional investment by the global scientific community in large well-coordinated trials of accessible agents and their combinations in LMICs. The search yielded 636, 175, and 930 trials, in the US, EU, and WHO trial registers, respectively. These trials covered 17 oral or potentially oral repurposed agents that are currently used as antimicrobials and immunomodulatory therapeutics and therefore have established safety. The available evidence regarding proposed mechanism of actions, clinical efficacy, and potential limitations is summarized. We also identified the need for large well-coordinated trials of accessible agents and their combinations in LMICs. Several repurposed agents have potential to be safe, available, and easily administrable to treat COVID-19. To prevent COVID-19 from becoming a neglected tropical disease, there is critical need for rapid and coordinated effort in their evaluation and the deployment of those found to be efficacious.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>SARS-CoV-2</kwd>
<kwd>severe acute respiratory syndrome-coronavirus 2</kwd>
<kwd>drug</kwd>
<kwd>repositioned</kwd>
<kwd>LMIC</kwd>
</kwd-group>
<counts>
<page-count count="35"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>This work was supported by a grant from the Lampert Byrd Foundation (MSH, KS, and OS). <ext-link ext-link-type="uri" xlink:href="http://www.lampertbyrdfoundation.org/">http://www.lampertbyrdfoundation.org/</ext-link></p>
<p>The funder did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>Not applicable</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The coronavirus disease 2019 (COVID-19) pandemic is having devastating long-term health and socioeconomic impact in low- and middle-income countries (LMICs). Worsening access to essential services, such as immunizations and routine care for preventable and chronic diseases, is also leading to excess all-cause mortality and morbidity<sup><xref ref-type="bibr" rid="c1">1</xref></sup>. Although lower population density and younger age demographics in some LMICs may be protective against high COVID-19 mortality<sup><xref ref-type="bibr" rid="c2">2</xref></sup>, poor health infrastructure, including a lack of hospital beds, health care providers and basic supplies, can lead to overwhelmed local health systems with relatively few cases<sup><xref ref-type="bibr" rid="c3">3</xref></sup>. Effectively responding to COVID-19 outbreaks in LMICs requires the development of new &#x201C;playbooks&#x201D; that are contextualized and locally relevant; following the path of high-income countries will most likely lead to wasted resources and ultimately poor epidemic control. Additionally, while vaccine research is moving forward at an unprecedented pace<sup><xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c5">5</xref></sup>, numerous barriers to effective widespread deployment exist<sup><xref ref-type="bibr" rid="c6">6</xref>,<xref ref-type="bibr" rid="c7">7</xref>, <xref ref-type="bibr" rid="c8">8</xref></sup>. And even with large immunization campaigns, treatments for those who cannot or do not receive the vaccine will still be needed. For many infectious diseases that are vaccine-preventable, antimicrobials remain powerful tools (e.g. bacterial meningitis, varicella, influenza): investment in pharmaceutical interventions should not be compromised in favor of vaccine development.</p>
<p>There is an urgent need for COVID-19 therapeutics that act early in the disease to prevent progression or work as pre- or post-exposure prophylaxis, and others that can treat severely or critically ill patients to prevent mortality. To date, we only have dexamethasone and possibly remdesivir to treat moderate to severe disease, and early non-peer reviewed press reports of improved patient outcomes with injectable monoclonal antibodies for mild illness. However, since the start of the pandemic, researchers have been screening and studying hundreds of available chemicals and drugs with antiviral properties that could be repurposed for treatment of COVID-19. Many of the agents currently in study are used for other diseases and have known safety profiles, which would allow for more rapid scale up of manufacturing at lower cost.</p>
<p>COVID-19 therapeutics must be of course be efficacious, but also accessible for patients in LMICs who may not have easy access to health centers. Oral, transmucosal or transdermal agents will be the easiest to administer at home or an outpatient clinic, followed by intranasal or inhaled formulations through a metered dose inhaler (MDI); these agents are typically less expensive and can be more widely distributed to patients. Subcutaneous, nebulized and intravenous formulations are much less easily administered as they can only be given in the context of a hospital or infusion center, and often require inpatient admission for administration. For example, the current intravenous (IV) formulation of remdesivir has intrinsic barriers to use due to the need for inpatient admission, particularly in countries with large rural populations that live far from health centers<sup><xref ref-type="bibr" rid="c9">9</xref></sup>.</p>
<p>Here we review current repurposed therapeutics candidates for treatment of COVID-19 currently in advanced clinical trials with potential for easy administration.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<p>Using the term &#x201C;COVID-19&#x201D; and its associated synonyms (&#x201C;COVID&#x201D;, &#x201C;SARS-CoV-2&#x201D;, &#x201C;severe acute respiratory syndrome coronavirus 2&#x201D;, &#x201C;2019-nCoV&#x201D;, &#x201C;2019 novel coronavirus&#x201D;, &#x201C;Wuhan coronavirus&#x201D;), we searched for trials registered in the United States National Library of Medicine (US NLM, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>), European Union Clinical Trials Register (EUCTR, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrialsregister.eu">clinicaltrialsregister.eu</ext-link>), and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP). These results were filtered to exclude non-interventional trials. We then excluded agents with no expected possibility of oral administration, that were rarely studied (n &#x003C; 3 in WHO ICTRP), or were already part of major guidelines, such as remdesivir.</p>
</sec>
<sec id="s3">
<title>Results</title>
<p>The results of the search as of January 14, 2021 are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>. The search yielded 636, 175, and 930 trials, in the US, EU, and WHO trial registers, respectively; of these trials, 88, 4, and 72 were completed, respectively. As the WHO ICTRP is a combination of the US and EU and other registers such as the Chinese Clinical Trial Registry (ChiCTR), we present a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the WHO ICTRP search (<xref rid="fig1" ref-type="fig">figure 1</xref>). There were 19 agents, of which 2 were grouped with another structurally similar agents. The final list of 17 oral or potentially oral repurposed agents are currently used as antimicrobials and immunomodulatory therapeutics and therefore have established safety. The agents with &#x003E;100 trial registered in any of the registers included: hydroxychloroquine, interferon, lopinavir/ritonavir, favipiravir, and ivermectin. Below is a summary of the available evidence regarding each agent&#x2019;s class, proposed mechanism of action, clinical efficacy, and potential limitations.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><title>COVID-19 candidate therapeutics with highest potential to be available and easily administrable in the near future</title></caption>
<graphic xlink:href="21253621v1_tbl1.tif"/>
<graphic xlink:href="21253621v1_tbl1a.tif"/>
<graphic xlink:href="21253621v1_tbl1b.tif"/>
</table-wrap>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><p>Flow diagram for trial search in World Health Organization International Clinical Trials Registry Platform (WHO ICTRP)</p></caption>
<graphic xlink:href="21253621v1_fig1.tif"/>
</fig>
<sec id="s3a">
<title>Hydroxychloroquine (HCQ)</title>
<p>While many trials have been undertaken to investigate the antimalarial and rheumatologic therapeutic CQ and HCQ, a hydroxy derivative of CQ, for treatment of COVID-19, results thus far have been largely negative. Here we focused on HCQ which is less toxic than CQ and has been shown to be more active against SARS-CoV-2 in vitro<sup><xref ref-type="bibr" rid="c10">10</xref></sup>. The SOLIDARITY trial of the WHO has released interim results as a pre-print and found that none of the 4 treatments tested, including HCQ, reduced 28-day mortality, initiation of ventilation, or duration of hospitalization <sup><xref ref-type="bibr" rid="c11">11</xref></sup>. More recently, the RECOVERY Collaborative found no difference in 28-day mortality in 1,561 patients randomized to HCQ or usual care<sup><xref ref-type="bibr" rid="c12">12</xref></sup>. Of note, median duration of symptoms at time of randomization was 9 days. Considering earlier treatment, again no difference in symptoms found when randomizing 491 patients to early treatment<sup><xref ref-type="bibr" rid="c13">13</xref></sup>. For prophylaxis, dozens of other trials are underway. One trial of post-exposure prophylaxis in community members and health workers found it to be ineffective <sup><xref ref-type="bibr" rid="c14">14</xref></sup>, though there were limitations of this pragmatic trial<sup><xref ref-type="bibr" rid="c15">15</xref></sup>. Another double-blind, placebo-controlled randomized clinical trial among healthcare workers showed no difference between post exposure prophylaxis of HCQ (600 mg daily for 8 weeks) versus placebo<sup><xref ref-type="bibr" rid="c16">16</xref></sup>. Another randomized trial of 1483 healthcare workers showing no reduction in incidence of COVID-19 using once or twice weekly HCQ pre-exposure prophylaxis<sup><xref ref-type="bibr" rid="c17">17</xref></sup>. In summary, all phases of illness have been studied and HCQ has not been found to be effective to date.</p>
</sec>
<sec id="s3b">
<title>Azithromycin</title>
<p>This macrolide antibiotic has been demonstrated to have a high selectivity index, based on half-maximal inhibitory concentration (IC50) divided by maximal cytotoxic concentration (CC50)<sup><xref ref-type="bibr" rid="c18">18</xref></sup>. However, in large randomized controlled trials (RCTs) it has been combined with HCQ or CQ and this combination has not shown to be of benefit, and has even shown signals of harm<sup><xref ref-type="bibr" rid="c19">19</xref>, <xref ref-type="bibr" rid="c20">20</xref>, <xref ref-type="bibr" rid="c21">21</xref>, <xref ref-type="bibr" rid="c22">22</xref></sup>. While no high-quality RCTs of azithromycin alone are available yet, a trial of mass administration to children in Niger resulted in 8 to 14-fold reductions in various coronaviruses based on PCR of the nasopharynx<sup><xref ref-type="bibr" rid="c23">23</xref></sup>. Further results from at least one large RCT are expected<sup><xref ref-type="bibr" rid="c24">24</xref></sup>.</p>
</sec>
<sec id="s3c">
<title>Interferons (particularly beta-1a and beta-1b)</title>
<p>As cytokine mediators that trigger the cellular immune response to viral infections, <sup><xref ref-type="bibr" rid="c25">25</xref></sup> interferons have been used and studied as antiviral therapy for several viral infections<sup><xref ref-type="bibr" rid="c26">26</xref></sup>. SARS-CoV-2 particularly has been shown to induce particularly low levels of interferon-1<sup><xref ref-type="bibr" rid="c27">27</xref></sup>. The IC50 of IFN beta-1a against SARS-CoV-2 was found <italic>in vitro</italic> using Vero E6 to increase with time from infection <sup><xref ref-type="bibr" rid="c28">28</xref></sup>. However, even as late as 96 hours from infection, high concentrations of IFN beta-1a, in the 50 to 5000 IU/mL range, completely protected Vero E6 cells. Notably, even at 5000 IU/mL, no morphological evidence of cytotoxicity due to IFN-beta-1a used in uninfected cells was noted. Clinically, IFN beta-1a has been evaluated in an open-label, randomized trial of 127 patients comparing LPV/r to triple therapy with LPV/r, IFN beta-1a, and ribavirin<sup><xref ref-type="bibr" rid="c29">29</xref></sup>. Triple therapy, when administered in the first 7 days, was superior in symptom relief, shortening duration of viral shedding, and shortening duration of hospital stay, all with no difference in adverse events<sup><xref ref-type="bibr" rid="c29">29</xref></sup>. Subgroup analysis of the trial suggested that IFN beta-1b was the driver of clinical differences between groups. More recently, an Iranian trial of 81 patients comparing the national protocol of HCQ plus LPV/r or atazanavir-ritonavir versus the same protocol plus subcutaneous IFN beta-1a showed no change in time to clinical response (the primary outcome), but did demonstrate decreased 28-day mortality in the IFN beta-1a group (19 versus 43&#x0025;, p=0.015)<sup><xref ref-type="bibr" rid="c30">30</xref></sup>. However, the SOLIDARITY trial did not show any benefit in mortality, progression to ventilation, or duration of hospitalization<sup><xref ref-type="bibr" rid="c11">11</xref></sup>.</p>
</sec>
<sec id="s3d">
<title>Lopinavir/ritonavir</title>
<p>Lopinavir is a well-studied protease inhibitor used to treat HIV type 1. It is administered in combination with ritonavir, a cytochrome P450 inhibitor, to increase its plasma half-life. As lopinavir/ritonavir (LPV/r) was identified as having <italic>in vitro</italic> activity against SARS-CoV, this agent was used in an open-label clinical trial in a Wuhan hospital (n=199), with participants randomized to LPV/r or standard of care (SOC)<sup><xref ref-type="bibr" rid="c31">31</xref></sup>. While there was a trend toward lower mortality (19.2&#x0025; vs 25&#x0025;), it was not statistically significant. It should be noted that 3 of the 19 patients who died in the experimental arm died less than 24 hours after randomization and never received LPV/r. However, the RECOVERY collaborative found in a large, multicenter randomized trial that this treatment was not associated with reduction in 28-day mortality, duration of hospitalization, or progression to ventilation or death<sup><xref ref-type="bibr" rid="c15">15</xref></sup>.</p>
</sec>
<sec id="s3e">
<title>Favipiravir</title>
<p>Favipiravir is another nucleoside analogue shown to have <italic>in vitro</italic> activity against SARS-CoV-2 in Vero cells, with an IC50 of 61.88 &#x00B5;M<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. Given the CC50 of &#x003E;400 &#x00B5;M, this yields a SI of &#x003E; 6.46. While this SI is less favorable than remdesivir&#x2019;s SI of &#x003E;129.87, favipiravir was demonstrated to be 100&#x0025; effective in a post-exposure prophylaxis mouse model after challenge with aerosolized Ebola virus, a virus for which it has a similar IC50<sup><xref ref-type="bibr" rid="c33">33</xref>, <xref ref-type="bibr" rid="c34">34</xref></sup>. Clinical data on favipiravir for SARS-CoV-2 are still limited. A trial of 80 patients compared favipiravir with interferon alpha against lopinavir/ritonavir with interferon alpha. While the favipiravir group had shorter time to viral clearance (4 vs 11 days), more frequent improvement in chest imaging (91 vs 62&#x0025;) and fewer adverse events (11&#x0025; vs 55&#x0025;), these results are limited by lack of blinding and randomization<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. An open-label, multicenter phase 3 clinical trial randomized 150 patients with mild to moderate COVID-19 to favipiravir versus standard of care, with a reported faster time to clinical cure and viral clearance by press release although the full data has not yet been published<sup><xref ref-type="bibr" rid="c35">35</xref></sup>.</p>
</sec>
<sec id="s3f">
<title>Ivermectin</title>
<p>Given its wide safety margin, ivermectin has been used broadly in mass distribution campaigns to treat illnesses such as onchocerciasis and lymphatic filariasis. More recently, it has been found to limit infection by dengue virus, West Nile Virus, and influenza, with antiviral activity attributed to inhibition of RNA virus interactions with the host nuclear transport proteins<sup><xref ref-type="bibr" rid="c36">36</xref></sup>. Ivermectin has been tested <italic>in vitro</italic> against SARS-CoV-2, demonstrating reduction in viral RNA in infected cells<sup><xref ref-type="bibr" rid="c36">36</xref></sup>. However, concentrations needed to achieve viral activity appear to be much higher than what standard doses can achieve in serum. Nonetheless, the drug can concentrate to higher levels in lung <sup><xref ref-type="bibr" rid="c37">37</xref>, <xref ref-type="bibr" rid="c38">38</xref></sup>. Possible evidence of this may come from a double-blind, randomized trial of 363 patients with PCR-proven SARS-CoV-2 in Dhaka, Bangladesh. Though not yet in pre-print, the team reported benefit in patients with mild-moderate disease, such as percent of patients experiencing late clinical recovery (23 vs 37&#x0025;, p&#x003C;0.03) <sup><xref ref-type="bibr" rid="c39">39</xref></sup>. It remains to be seen if this will be born out after peer review and in other trials. Lastly, incorporating ivermectin into COVID-19 treatment could have the added benefit of preventing <italic>Strongyloides</italic> hyperinfection in patients treated with dexamethasone.<sup><xref ref-type="bibr" rid="c40">40</xref></sup> As <italic>Strongyloides stercoralis</italic> is hyper-endemic in many LMICs, this could significantly reduce morbidity.</p>
</sec>
<sec id="s3g">
<title>Nitazoxanide</title>
<p>While not on the WHO List of Essential Medicines, the antiparasitic nitazoxanide has a long history of safety and tolerability since its discovery 30 years ago. It has been investigated as an antiviral previously against MERS in 2016 <sup><xref ref-type="bibr" rid="c41">41</xref></sup>, as well as influenza, with variable results<sup><xref ref-type="bibr" rid="c42">42</xref>, <xref ref-type="bibr" rid="c43">43</xref></sup>. Against SARS-CoV-2, nitazoxanide has a promising ratio of plasma concentration to IC50 for SARS-CoV-2 of 14:1 with standard dosing and could be produced for at a daily cost of &#x0024;0.10 <sup><xref ref-type="bibr" rid="c44">44</xref></sup>. As of January 14, 2021, while 24 clinical trials of nitazoxanide are listed on <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>, only three have been completed. Notably, the SARITA-2 trial in Brazil, which showed no difference in symptoms at 5 days but did decrease viral load with no serious adverse events noted <sup><xref ref-type="bibr" rid="c45">45</xref></sup>.</p>
</sec>
<sec id="s3h">
<title>Camostat, Nafamostat, and Bromohexine</title>
<p>Camostat and the closely related nafamostat are serine protease inhibitors with decades of clinical use in disseminated intravascular coagulation and pancreatitis, and are well-tolerated<sup><xref ref-type="bibr" rid="c46">46</xref></sup>. Unlike other agents for SARS-CoV-2, they act at on a human target rather than a viral target called transmembrane serine protease 2 (TMPRSS2)<sup><xref ref-type="bibr" rid="c47">47</xref></sup>. As this is a necessary agent in the viral spike protein&#x2019;s function, these agents can partially inhibit SARS-CoV-2 entry into lung epithelial cells. This may be true of other viral infections as well, as an attenuated course of H1N1 influenza was noted in <italic>Tmprss2</italic> knockout mice. While both agents show promising <italic>in vitro</italic> data, nafamostat inhibited SARS-CoV-2 S-mediated entry into host cells with approximately 15-fold-higher efficiency than camostat at a low EC50 <sup><xref ref-type="bibr" rid="c48">48</xref></sup>. However, due to the requirement for intravenous administration, nafamostat has been overshadowed by oral camostat in ongoing clinical trials. Lastly, the mucolytic bromohexine, which also inhibits TMPRSS2 protease, was found ineffective in a small (n=18) randomized trial.<sup><xref ref-type="bibr" rid="c49">49</xref>, <xref ref-type="bibr" rid="c50">50</xref></sup></p>
</sec>
<sec id="s3i">
<title>Niclosamide</title>
<p>Niclosamide is another antiparasitic with a well-established safety profile that is currently on the WHO Model List of Essential Medicines <sup><xref ref-type="bibr" rid="c51">51</xref></sup>. Although it is used primarily for treatment of cestode infections, niclosamide has been found to have a low IC50 against SARS-CoV-2. Possible mechanistic explanations for this include blocking endocytosis, inhibition of viral replication, and inhibiting receptor mediated endocytosis <sup><xref ref-type="bibr" rid="c52">52</xref></sup>. Despite its potential, clinical trials of this agent are very limited.</p>
</sec>
<sec id="s3j">
<title>Umifenovir</title>
<p>Originally licensed in Russia in 1993 for treatment and prophylaxis of Influenza, umifenovir was found to inhibit SARS-CoV reproduction <italic>in vitro</italic> and clinical trials were quickly undertaken. A retrospective review of 81 hospitalized, non-intensive care unit patients with COVID-19 in China showed no significant differences in outcomes other than longer hospital stays in the umifenovir group<sup><xref ref-type="bibr" rid="c53">53</xref></sup>. More recently, a meta-analysis of 12 studies, both retrospective and prospective, including a total of 1052 patients, found only a slightly higher rate of PCR-negative testing on hospital day 14 (CI: 1.04 to 1.55)<sup><xref ref-type="bibr" rid="c54">54</xref></sup>. Given that the end points of the included studies were predominantly symptomatic and laboratory-based with some composite end point, no mortality comparison was made.</p>
</sec>
<sec id="s3k">
<title>Daclatasvir/sofosbuvir and Ledipasvir/Sofosbuvir</title>
<p>The combination of sofosbuvir and either daclatasvir or ledipasvir has been used to treat hepatitis C and has proven effective for that indication and was well tolerated<sup><xref ref-type="bibr" rid="c55">55</xref></sup>. More recently, <italic>in silico</italic> studies have been carried out identifying both sofosbuvir and daclatasvir as potential inhibitors of SARS-CoV-2<sup><xref ref-type="bibr" rid="c56">56</xref>, <xref ref-type="bibr" rid="c57">57</xref>, <xref ref-type="bibr" rid="c58">58</xref></sup>. This combination offer well-established safety and tolerability as combination therapy and has been shown to be safe in patients with renal impairment<sup><xref ref-type="bibr" rid="c25">25</xref></sup>. Three small trials, sometimes in combination with ribavirin, have been published. All three demonstrated reduced mortality in the treatment group, one achieving statistical significance (p=0.02)<sup><xref ref-type="bibr" rid="c59">59</xref>, <xref ref-type="bibr" rid="c60">60</xref>, <xref ref-type="bibr" rid="c61">61</xref></sup>.</p>
</sec>
<sec id="s3l">
<title>Molnupiravir (formerly MK-4482 and EIDD-2801)</title>
<p>Molnupiravir is an orally bioavailable prodrug of beta-D-N4-hydroxycyctidine (NHC) that has demonstrated antiviral activity against Venezuelan Equine Encephalitis Virus<sup><xref ref-type="bibr" rid="c62">62</xref></sup>. More recently, it has shown <italic>in vitro</italic> activity against SARS-CoV-2 with low IC50s <sup><xref ref-type="bibr" rid="c63">63</xref></sup>. When testing for cytotoxicity to establish an estimated therapeutic window, NHC did not cause significant mutagenesis at concentrations as high as 100 &#x00B5;M. Even using the higher IC50 range, this yields a favorable SI of &#x003E;300 <sup><xref ref-type="bibr" rid="c63">63</xref></sup>. Lastly, oral molnupiravir improved lung function in mice infected with MERS-CoV. Currently, it is in phase 2 trials in inpatient and outpatient settings<sup><xref ref-type="bibr" rid="c64">64</xref></sup>.</p>
</sec>
<sec id="s3m">
<title>Bemcentinib</title>
<p>Axl is one of a group of tyrosine kinase receptors which has previously been shown to mediate the entry of Zika virus<sup><xref ref-type="bibr" rid="c65">65</xref></sup>. More recently, an <italic>in silico</italic> screening of approximately 9000 United States Food and Drug Administration (FDA) approved drugs for their potential to interfere with the ability of SARS-CoV-2 to evade innate immune recognition identified the Axl kinase inhibitor bemcentinib as a promising candidate<sup><xref ref-type="bibr" rid="c66">66</xref></sup>. Moreover, bemcentinib may prevent downregulation of the innate immune response, including IFN production. Lastly, it may inhibit viral cell entry as with Zika virus and others, such as West Nile virus and Ebola virus. Bemcentinib was moved rapidly into the United Kingdom&#x2019;s ACcelerating COVID-19 dRUG Development (ACCORD) trial and robust clinical data are anticipated.</p>
</sec>
<sec id="s3n">
<title>Fingolimod and opaganib</title>
<p>The role of modulating Sphingosine 1 phosphate (S1P) pathway either by enhancing or suppressing it is a controversial and sometimes contradictory in terms of the treatment of COVID-19. S1P analogues are being used as part of immune therapy with patients with multiple relapsing multiple sclerosis. Fingolimod is an oral agent that, once phosphorylated, acts as an analogue on S1PR receptors. S1P and its receptor S1P control T cell egress from the thymus and secondary lymphoid organs (SLO) as well. By activating one subtype the S1P receptor (mainly subtype I), na&#x00EF;ve and central memory T cells are retained in SLO thus inducing lymphocytopenia<sup><xref ref-type="bibr" rid="c67">67</xref></sup>. This was proven to be beneficial for patient with autoimmune disease mainly multiple sclerosis where it was proven to reduce relapse rates in clinical trials<sup><xref ref-type="bibr" rid="c68">68</xref></sup>. The proposed mechanism of the beneficial effect is that Fingolimod traps newly generated encephalitogenic T cells in lymph nodes and prevents migration to the CNS<sup><xref ref-type="bibr" rid="c69">69</xref></sup>. Even though the physiologic response to viral infections involves lymphocyte migration, Fingolimod does not seem to affect memory B cells and its effect only targets native and central B cells, thus still allowing key immune system responses during therapy. This was proven by several infection models that showed Fingolimod therapy did not affect virus-specific cytotoxic T cells generation<sup><xref ref-type="bibr" rid="c70">70</xref></sup>. Initial interest to S1P blockade for COVID-19 treatment sprung when several case reports for patients on Fingolimod therapy were diagnosed with COVID-19 and all had very good outcomes<sup><xref ref-type="bibr" rid="c71">71</xref>, <xref ref-type="bibr" rid="c72">72</xref></sup>. Given that COVID-19-induced &#x2018;cytokine storm&#x2019; is a central feature of severe COVID-19, immunomodulatory therapy such as Fingolimod became a subject of interest. Acute lung injury and pulmonary edema which have been extensively described in severe COVID-19 patients are characterized by an increased in vascular permeability. S1P was proven to be a potent angiogenic factor that enhances lung cell wall integrity and an inhibitor of vascular permeability and alveolar flooding in pre-clinical models of acute lung injury<sup><xref ref-type="bibr" rid="c73">73</xref></sup>. Given that Fingolimod is a S1P analogue, it has been postulated that Fingolimod might also decrease COVID-19-associated increased vascular permeability and associated lung injury<sup><xref ref-type="bibr" rid="c74">74</xref></sup>. One phase 2 trial was planned to investigate the role of Fingolimod in COVID-19 patients but was later withdrawn. Another point to note is the unclear effect of Fingolimod-induced lymphopenia would have on COVID-19 patients given that lymphopenia is associated with worse outcomes in COVID-19 patients<sup><xref ref-type="bibr" rid="c75">75</xref></sup>. We could not identify any other trials investigating Fingolimod in COVID-19 patients.</p>
<p>Opaganib is another oral agent that modulates the S1P pathway by inhibiting the enzyme sphingosine kinase isoenzyme 2 ShpK2 thus decreasing levels of S1P. S1P has been shown to be secreted by platelets, monocytes and mast cells in response to inflammation thus promoting inflammatory cascades at the site of injury<sup><xref ref-type="bibr" rid="c76">76</xref>, <xref ref-type="bibr" rid="c77">77</xref></sup>. In addition, S1P mimics TNF-alpha effect in increasing the expression of cyclooxygenase 2 enzyme and prostaglandin E2<sup><xref ref-type="bibr" rid="c78">78</xref></sup>. Thus blocking S1P may provide anti-inflammatory properties. That was demonstrated in rodent models of arthritis<sup><xref ref-type="bibr" rid="c79">79</xref></sup>. Genetic deletion of SPhK2 in mice models conferred protection against Pseudomonas aeruginosa mediated lung inflammation<sup><xref ref-type="bibr" rid="c80">80</xref></sup>. Although no in-vitro evaluation of antiviral activity of opaganib against the SARS CoV2 virus have been published, there has been previous publications demonstrating antiviral effects of targeting the SphK2 enzyme against the Chikungunya virus<sup><xref ref-type="bibr" rid="c81">81</xref></sup>, Influenza viruses<sup><xref ref-type="bibr" rid="c82">82</xref></sup>. Based on the postulated anti-inflammatory and antiviral properties, Opaganib was used on the basis of compassionate use in Israel in 7 patients with reported improvement in both clinical and laboratory parameters<sup><xref ref-type="bibr" rid="c83">83</xref></sup>. Two trials have since then assessed the role of Opaganib. A phase 2 trial enrolled 40 patients in the US, but was not powered for statistical significance and was focused on efficacy defined by reduction in total oxygen requirement over the course of treatment up to 14 days (NCT04414618). Another global phase 2/3 trial of Opaganib in patients with severe COVID-19 pneumonia (NCT04467840) is currently enrolling patients.</p>
</sec>
<sec id="s3o">
<title>Maraviroc</title>
<p>Computational bioinformatics have identified chemokine receptor antagonist maraviroc (MRV) as a potential antagonist to the SARS C0V2 main protease M<sup>pro</sup>, 3CL <sup>pro</sup>, the function of which is regulating replication and transcription by cleaving polyproteins to generate non-structural proteins (NSPs). From a replicase-transcriptase complex. Maraviroc was found to bind to the substrate-binding pocket of M<sup>pro</sup> forming a significant number of non-covalent interactions<sup><xref ref-type="bibr" rid="c84">84</xref></sup>. This has not been substantiated with in vitro studies as MRV had EC<sub>50</sub> values above 40 &#x00B5;M (compared with Remdesevir EC<sub>50</sub> of 1.1)<sup><xref ref-type="bibr" rid="c85">85</xref></sup> thus making MRV an unattractive agent clinically. Nevertheless given the pressing needs created by the pandemic, 3 trials were initiated to investigate the potential benefit of maraviroc for the treatment of COVID-19 patients: 2 are currently recruiting in Barcelona Spain<sup><xref ref-type="bibr" rid="c86">86</xref></sup> and Rhode Island Providence Hospital USA<sup><xref ref-type="bibr" rid="c78">78</xref></sup>. A third trial in Mexico City has maraviroc alone or maraviroc in addition to favipiravir as treatment arms is not yet recruiting.</p>
</sec>
<sec id="s3p">
<title>Doxycycline</title>
<p>Doxycycline is another potentially repurposed drugs to treat COVID-19 given its antiviral and anti-inflammatory properties. It has showed in vitro activity against SARS-CoV2 infected Vero E cells with median effective concentration EC50 comparable with oral and parenteral formulation <sup><xref ref-type="bibr" rid="c87">87</xref></sup> and has been shown to exhibit antiviral activity against several RNA viruses like dengue virus. The proposed antiviral effect mechanism may be due to upregulation of the intracellular zinc finger antiviral protein which in turns binds to specific viral mRNAs and represses RNA translation, an effect previously demonstrated with Ebola, HIV, Zika and Influenza A viruses <sup><xref ref-type="bibr" rid="c88">88</xref>, <xref ref-type="bibr" rid="c89">89</xref></sup>. In addition, doxycycline has been shown to stimulate pro-inflammatory cytokines including interleukin-6 and tumor necrosis factor-alpha<sup><xref ref-type="bibr" rid="c90">90</xref></sup> and could inhibit SARS CoV2 papain-like protease <sup><xref ref-type="bibr" rid="c91">91</xref>, <xref ref-type="bibr" rid="c92">92</xref></sup>. The Oxford Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE) which targeted adults with COVID-19 in the outpatient includes an arm for usual care plus doxycycline. In another small scale trial, ivermectin/doxycycline combination vs standard of care was shown to reduce time to recovery and disease progression<sup><xref ref-type="bibr" rid="c93">93</xref></sup>.</p>
</sec>
<sec id="s3q">
<title>JAK/STAT inhibitors</title>
<p>In an attempt to mitigate the hyper inflammatory cytokine storm associated with COVID-19, JAK/STAT inhibitors ruxolitinib and baricitinib were both investigated as potential therapeutics. Both inhibit the intracellular pathways of cytokines known to be elevated in severe COVID-19. Baricitinib was also identified as a numb-associated kinase <sup><xref ref-type="bibr" rid="c25">25</xref></sup>, with a particularly high affinity for AP-2 associated protein Kinase-1, an important regulator of clathrin-mediated viral endocytosis, and thus could potentially inhibit intracellular viral replication<sup><xref ref-type="bibr" rid="c94">94</xref>, <xref ref-type="bibr" rid="c95">95</xref></sup>. Several cases series have demonstrated a beneficial effect of baricitinib in treatment of COVID-19 patients<sup><xref ref-type="bibr" rid="c96">96</xref>, <xref ref-type="bibr" rid="c97">97</xref></sup>. The International Society for Influenza and other Respiratory Virus Disease Antiviral Group Conference reported that the addition of baricitinib to remdesivir in patients hospitalized with COVID-19 was associated with shorter hospital stay (8 vs 7 days, p=0.04) and that there was a decrease in death, though not achieving statistical significance, for death at 29 days in the baricitinib group (5.1 vs 7.8&#x0025;, p=0.09)<sup><xref ref-type="bibr" rid="c98">98</xref></sup>. The ACTT-2 trial (Adaptive COVID-19 Treatment Trial-2) was a multinational, multicenter placebo-controlled double randomized trial that demonstrated the combination therapy of remdesivir and baricitinib vs remdesivir alone provided a lower time to recovery in patients requiring high-flow oxygen <sup><xref ref-type="bibr" rid="c9">9</xref></sup>. Another JAK1/2 inhibitor, ruxolitinib, was studied in a small randomized trial in Wuhan, China, patients treated with ruxolitinib did not have statistically significant reductions in time to clinical improvement nor survival <sup><xref ref-type="bibr" rid="c32">32</xref></sup>. An unpublished Phase III multicenter, randomized, double blind placebo-controlled trial comparing ruxolitinib with standards of care (RUXCOVID) failed to meet its primary endpoint of severe complications <sup><xref ref-type="bibr" rid="c99">99</xref></sup>.</p>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>This review of candidate COVID-19 therapeutics highlights some of the extensive work already completed in screening individual compounds. It should be noted that the therapeutics arm of the Access to COVID-19 Tools Accelerator, with funding from the Bill and Melinda Gates Foundation, the Wellcome Trust, the Mastercard Impact Fund, National Institutes of Health, and others, have worked to advance this agenda substantially, coordinating the sharing of preclinical compound libraries and clinical research<sup><xref ref-type="bibr" rid="c100">100</xref>, <xref ref-type="bibr" rid="c101">101</xref></sup>. Another example of such work is the &#x2018;Accelerating COVID-19 Therapeutic Interventions and Vaccines&#x2019; or &#x2018;ACTIV&#x2019; public-private consortium, involving United States&#x2019; government agencies, the European Medicines Agency, and private industry<sup><xref ref-type="bibr" rid="c102">102</xref></sup>. More critical work remains to be added to the achievements of this team and others toward the design and implementation of adaptive, pragmatic clinical trials specifically targeted for the resource-constrained settings of LMICs. Of note, given the lessons learned from treatments for other viruses such as HIV and hepatitis C virus, it is possible that combination therapy could prove more beneficial than monotherapy alone. The following framework, adapted from other proposed frameworks<sup><xref ref-type="bibr" rid="c103">103</xref></sup>, has an emphasis on rapid discovery of agents for LMICs. It highlights the aim of advancing candidate agents from pre-clinical screening of compounds to clinical trials, with an intentional focus on the unmet needs in LMICs (<xref rid="fig2" ref-type="fig">fig 2</xref>).</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><p>Proposed workflow for identifying effective COVID-19 therapeutics</p></caption>
<graphic xlink:href="21253621v1_fig2.tif"/>
</fig>
<p>Using a library of known compounds has the benefit not only of rapid development and established drug safety profiles, but also higher likelihood of avoiding licensing costs, making delivery to LMICs both more rapid and less costly to facilitate widespread access. Initial identification of known candidate agents for treatment of COVID-19 has mostly been achieved with computer modeling, or <italic>in silico</italic> testing<sup><xref ref-type="bibr" rid="c104">104</xref></sup>. Notable achievements on this front include protein interaction mapping<sup><xref ref-type="bibr" rid="c105">105</xref></sup>, which yielded both clinical and pre-clinical candidate agents as well as the screening of agents with established human safety profiles such as the ReFRAME library. This catalog of over 12,000 compounds has already been used to identify candidates for treatment of other infectious diseases such as tuberculosis and cryptosporidiosis<sup><xref ref-type="bibr" rid="c106">106</xref></sup>. Using this technique, Riva <italic>et al.</italic> reported the identification of new COVID-19 candidate agents such as apilimod<sup><xref ref-type="bibr" rid="c107">107</xref></sup>.</p>
<p>While screening of individual agents has progressed rapidly, screening for combination therapy or &#x201C;cocktails&#x201D; has been less robust, particularly when excluding trials using combinations including HCQ. While no agents may be highly effective alone, combinations of various agents may prove efficacious, as can be seen in HIV and hepatitis C<sup><xref ref-type="bibr" rid="c108">108</xref>, <xref ref-type="bibr" rid="c109">109</xref></sup>. In these cases, preventing resistance to therapy through mutations is an important driver of combination therapy. Another rationale for combination therapy is targeting multiple points in regulatory circuits, which are often redundant to help maintain homeostasis. Well-designed pre-clinical studies with such targets in mind can help yield effective combination therapies<sup><xref ref-type="bibr" rid="c110">110</xref></sup>. Lastly, combination therapy, specifically using drug repurposing, has been a demonstrated means to address urgent needs for drugs in infectious disease when research lags behind clinical need<sup><xref ref-type="bibr" rid="c111">111</xref></sup>.</p>
<p>One early example of screening for combination therapies, though in preprint as of 20 November 2020, identified 16 synergistic combinations, but also 8 antagonistic combinations<sup><xref ref-type="bibr" rid="c112">112</xref></sup>. For example, synergy was found between nitazoxanide and several other compounds, and strong antagonism was found <italic>in vitro</italic> with the combination of remdesivir and hydroxychloroquine. While some clinical trials of &#x201C;cocktail&#x201D; therapy for COVID-19 are underway (interferon beta-1a with remdesivir, nitazoxanide with atazanavir, and nitazoxanide with ivermectin to name a few), <italic>a priori</italic> screening for candidate COVID-19 therapeutic combinations <italic>in silico</italic> followed by <italic>in vitro</italic> synergy studies could lead more rapidly to clinical trials of effective treatment of COVID-19 in LMICs and elsewhere. However, the complexities associated manufacturing and administration of combination therapies should be considered, and those with potential for affordability and availability in LMICs can be prioritized.</p>
<p>Despite a large number of ongoing clinical trials worldwide, only a small portion of these are adequately powered, randomized double-blinded placebo controlled clinical trials. Moreover, an even smaller fraction are currently being conducted in LMICs, likely due to several barriers. First, large clinical trials in LMICs are often require highly collaborative international partnerships. In-person site visits and collaboration, often integral to such work, has been curtailed in an effort to control the very pandemic they would seek to address. Second, diagnostic resources and capacity are more limited in LMICs compared to many higher-income countries. This limitation of available and accurate testing in LMICs could pose a threefold challenge: impeding modeling of the spread of the pandemic to facilitate well-planned trials, reducing identification and recruitment of proven cases, and further limiting diagnostic capacity for direct research use. Lastly, these interventions require trial expertise in multiple clinical settings: as treatment of severe, hospitalizing disease to reduce morbidity and mortality, as treatment of mild or moderate disease to reduce progression and transmission of disease, and as prophylactic or presumptive treatment. Indeed, targeted prophylaxis or presumptive treatment to high risk groups may be one of the more promising roles for such agents, with examples of success in LMICs with meningococcal disease<sup><xref ref-type="bibr" rid="c113">113</xref></sup> and malaria<sup><xref ref-type="bibr" rid="c114">114</xref></sup>.</p>
<p>Though these challenges are significant, they are not insurmountable. New drug candidates appear rapidly and a coordinated adaptive trial design should be used. As the clinical context of this disease is global, focused clinical endpoints that do not require extensive resources can provide rigor without burdening researchers with added cost and complexity. Designing such trials requires broad expertise and thus broad collaboration. Such trial protocols can be then distributed, decreasing burdens on aspiring trialists and increasing sample sizes and sites, and thus improving power and generalizability of findings. Indeed, some or all of the above approaches have been used by groups such as RECOVERY, SOLIDARITY, and ACTT1-3, to name a few. These trials have provided some of the most actionable results to date, with positive and negative results. An example of work to coordinate such large efforts with open collaboration is the COVID-19 Clinical Research Coalition, which has called for and facilitated large RCTs in LMIC and has made research materials available for these studies<sup><xref ref-type="bibr" rid="c86">86</xref></sup>. Many of the agents in these trials, such as hydroxychloroquine, are now of lower interest given repeated negative findings. However, this framework of collaboration, in combination with the screening techniques discussed above, could lead more rapidly to much-needed therapies.</p>
</sec>
<sec id="s5">
<title>Conclusions</title>
<p>Particularly for LMICs, injectable tools against COVID-19 - whether vaccines, or therapeutics such as remdesivir and monoclonal antibodies which are not included in this review - present challenges in production, distribution, and uptake. Agents that are accessible and easily administered, as well as combinations of such agents, can and should be emphasized in pragmatic, adaptive clinical trials specifically targeted for LMICs. Such efforts could yield not only more rapid results but also a truly global impact whereby we can prevent COVID-19 from becoming a neglected tropical disease.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>All data are fully available without restriction.
The data are held in public repositories: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrialsregister.eu">www.clinicaltrialsregister.eu</ext-link>, and <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/trialsearch">https://apps.who.int/trialsearch</ext-link>.</p>
<p><ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</ext-link></p>
<p><ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</ext-link></p>
<p><ext-link ext-link-type="uri" xlink:href="https://apps.who.int/trialsearch">https://apps.who.int/trialsearch</ext-link></p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We thank Richard Feachem and Kathryn Vosburg from the Pandemic Response Initiative, Institute for Global Health Sciences, University of California, UCSF, for their guidance on and review of the manuscript.</p>
</ack>
<sec id="s6">
<title>Funding</title>
<p>This work was supported by funding from the Lampert Byrd Foundation.</p>
</sec>
<sec id="s7">
<title>Co-author contact information</title>
<p>Daniel Maxwell, UT Southwestern Medical Center, <email>Daniel.Maxwell@UTSouthwestern.edu</email></p>
<p>Kelly C. Sanders, University of California, San Francisco (UCSF), <email>Kelly.Sanders@ucsf.edu</email></p>
<p>Oliver Sabot, UCSF, <email>ojsabot15@gmail.com</email></p>
<p>Ahmad Hachem, UT Southwestern Medical Center, <email>Ahmad.Hachem@UTSouthwestern.edu</email></p>
<p>Alejandro Llanos-Cuentas, Universidad Peruana Cayetano Heredia (UPCH), <email>alejandro.llanos.c@upch.pe</email></p>
<p>Ally Olotu, Ifakara Health Institute, <email>aolotu@ihi.or.tz</email></p>
<p>Roly Gosling, UCSF, <email>roly.gosling@ucsf.edu</email></p>
<p>James B. Cutrell, UT Southwestern Medical Center, <email>James.Cutrell@UTSouthwestern.edu</email></p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Alwan</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Burgess</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Ashworth</surname> <given-names>S</given-names></string-name>, <string-name><surname>Beale</surname> <given-names>R</given-names></string-name>, <string-name><surname>Bhadelia</surname> <given-names>N</given-names></string-name>, <string-name><surname>Bogaert</surname> <given-names>D</given-names></string-name>, <string-name><surname>Dowd</surname> <given-names>J</given-names></string-name>, <string-name><surname>Eckerle</surname> <given-names>I</given-names></string-name>, <string-name><surname>Goldman</surname> <given-names>LR</given-names></string-name>, <string-name><surname>Greenhalgh</surname> <given-names>T</given-names></string-name>, <year>2020</year>. <article-title>Scientific consensus on the COVID-19 pandemic: we need to act now</article-title>. <source>The Lancet</source> <volume>396</volume>: <fpage>e71</fpage>&#x2013;<lpage>e72</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="website"><string-name><surname>Shuchman</surname> <given-names>M</given-names></string-name>, <year>2020</year>. <source>Low-and middle-income countries face up to COVID-19</source>. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/d41591-020-00020-2">https://www.nature.com/articles/d41591-020-00020-2</ext-link>. Accessed <date-in-citation content-type="access-date">27 Oct, 2020</date-in-citation>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="website"><collab>United Nations Development Programme</collab>, <year>2020</year>. <source>COVID&#x2370;l19 and health system vulnerabilities in the poorest developing countries</source>. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.undp.org/content/dam/undp/library/km-qap/Transitions%20Series/undp-gpn-transitions-series-health-COVID-19_and_Health_System_Vulnerabilities_EN.pdf">https://www.undp.org/content/dam/undp/library/km-qap/Transitions%20Series/undp-gpn-transitions-series-health-COVID-19_and_Health_System_Vulnerabilities_EN.pdf</ext-link>. Accessed <date-in-citation content-type="access-date">Nov 22, 2020</date-in-citation>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><given-names>Thanh</given-names> <surname>Le T</surname></string-name>, <string-name><surname>Andreadakis</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>A</given-names></string-name>, <string-name><surname>G&#x00F3;mez Rom&#x00E1;n</surname> <given-names>R</given-names></string-name>, <string-name><surname>Tollefsen</surname> <given-names>S</given-names></string-name>, <string-name><surname>Saville</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mayhew</surname> <given-names>S</given-names></string-name>, <year>2020</year>. <article-title>The COVID-19 vaccine development landscape</article-title>. <source>Nature Reviews Drug Discovery</source> <volume>19</volume>: <fpage>305</fpage>&#x2013;<lpage>306</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Peeples</surname> <given-names>L</given-names></string-name>, <year>2020</year>. <article-title>News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>117</volume>: <fpage>8218</fpage>&#x2013;<lpage>8221</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Hoest</surname> <given-names>C</given-names></string-name>, <string-name><surname>Seidman</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>G</given-names></string-name>, <string-name><surname>Platts-Mills</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Ali</surname> <given-names>A</given-names></string-name>, <string-name><surname>Olortegui</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Bessong</surname> <given-names>P</given-names></string-name>, <string-name><surname>Chandyo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Babji</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mohan</surname> <given-names>VR</given-names></string-name>, <string-name><surname>Mondal</surname> <given-names>D</given-names></string-name>, <string-name><surname>Mahfuz</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mduma</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Nyathi</surname> <given-names>E</given-names></string-name>, <string-name><surname>Abreu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>W</given-names></string-name>, <string-name><surname>Mason</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Knobler</surname> <given-names>SL</given-names></string-name>, <year>2017</year>. <article-title>Vaccine coverage and adherence to EPI schedules in eight resource poor settings in the MAL-ED cohort study</article-title>. <source>Vaccine</source> <volume>35</volume>: <fpage>443</fpage>&#x2013;<lpage>451</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Thielmann</surname> <given-names>A</given-names></string-name>, <string-name><surname>Puth</surname> <given-names>M-T</given-names></string-name>, <string-name><surname>Kersting</surname> <given-names>C</given-names></string-name>, <string-name><surname>Porz</surname> <given-names>J</given-names></string-name>, <string-name><surname>Weltermann</surname> <given-names>B</given-names></string-name>, <year>2019</year>. <article-title>Vaccine cold chain in general practices: A prospective study in 75 refrigerators (Keep Cool study)</article-title>. <source>PLOS ONE</source> <volume>14</volume>: <fpage>e0224972</fpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Yamey</surname> <given-names>G</given-names></string-name>, <string-name><surname>Sch&#x00E4;ferhoff</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hatchett</surname> <given-names>R</given-names></string-name>, <string-name><surname>Pate</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>F</given-names></string-name>, <string-name><surname>McDade</surname> <given-names>KK</given-names></string-name>, <year>2020</year>. <article-title>Ensuring global access to COVID-19 vaccines</article-title>. <source>The Lancet</source> <volume>395</volume>: <fpage>1405</fpage>&#x2013;<lpage>1406</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Beigel</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Tomashek</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Dodd</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Mehta</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Zingman</surname> <given-names>BS</given-names></string-name>, <string-name><surname>Kalil</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Hohmann</surname> <given-names>E</given-names></string-name>, <string-name><surname>Chu</surname> <given-names>HY</given-names></string-name>, <string-name><surname>Luetkemeyer</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kline</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lopez De Castilla</surname> <given-names>D</given-names></string-name>, <string-name><surname>Finberg</surname> <given-names>RW</given-names></string-name>, <string-name><surname>Dierberg</surname> <given-names>K</given-names></string-name>, <string-name><surname>Tapson</surname> <given-names>V</given-names></string-name>, <string-name><surname>Hsieh</surname> <given-names>L</given-names></string-name>, <string-name><surname>Patterson</surname> <given-names>TF</given-names></string-name>, <string-name><surname>Paredes</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sweeney</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Short</surname> <given-names>WR</given-names></string-name>, <string-name><surname>Touloumi</surname> <given-names>G</given-names></string-name>, <string-name><surname>Lye</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Ohmagari</surname> <given-names>N</given-names></string-name>, <string-name><surname>Oh</surname> <given-names>M-D</given-names></string-name>, <string-name><surname>Ruiz-Palacios</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Benfield</surname> <given-names>T</given-names></string-name>, <string-name><surname>F&#x00E4;tkenheuer</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kortepeter</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Atmar</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Creech</surname> <given-names>CB</given-names></string-name>, <string-name><surname>Lundgren</surname> <given-names>J</given-names></string-name>, <string-name><surname>Babiker</surname> <given-names>AG</given-names></string-name>, <string-name><surname>Pett</surname> <given-names>S</given-names></string-name>, <string-name><surname>Neaton</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Burgess</surname> <given-names>TH</given-names></string-name>, <string-name><surname>Bonnett</surname> <given-names>T</given-names></string-name>, <string-name><surname>Green</surname> <given-names>M</given-names></string-name>, <string-name><surname>Makowski</surname> <given-names>M</given-names></string-name>, <string-name><surname>Osinusi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Nayak</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lane</surname> <given-names>HC</given-names></string-name>, <year>2020</year>. <article-title>Remdesivir for the Treatment of Covid-19 &#x2014; Preliminary Report</article-title>. <source>New England Journal of Medicine</source>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Yao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Ye</surname> <given-names>F</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cui</surname> <given-names>C</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>B</given-names></string-name>, <string-name><surname>Niu</surname> <given-names>P</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>L</given-names></string-name>, <string-name><surname>Dong</surname> <given-names>E</given-names></string-name>, <string-name><surname>Song</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zhan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>R</given-names></string-name>, <string-name><surname>Li</surname> <given-names>H</given-names></string-name>, <string-name><surname>Tan</surname> <given-names>W</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>D</given-names></string-name>, <year>2020</year>. <article-title>In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</article-title>. <source>Clin Infect Dis</source> <volume>71</volume>: <fpage>732</fpage>&#x2013;<lpage>739</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><collab>WHO Solidarity Trial Consortium</collab>, <year>2020</year>. <article-title>Repurposed antiviral drugs for COVID-19&#x2013;interim WHO SOLIDARITY trial results</article-title>. <source>medRxiv</source> doi: <pub-id pub-id-type="doi">10.1101/2020.10.15.20209817v1</pub-id>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><year>2020</year>. <article-title>Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19</article-title>. <source>New England Journal of Medicine</source>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Skipper</surname> <given-names>CP</given-names></string-name>, <string-name><surname>Pastick</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Engen</surname> <given-names>NW</given-names></string-name>, <string-name><surname>Bangdiwala</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Abassi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lofgren</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Williams</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Okafor</surname> <given-names>EC</given-names></string-name>, <string-name><surname>Pullen</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Nicol</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Nascene</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Hullsiek</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Luke</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lother</surname> <given-names>SA</given-names></string-name>, <string-name><surname>MacKenzie</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Drobot</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kelly</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>IS</given-names></string-name>, <string-name><surname>Zarychanski</surname> <given-names>R</given-names></string-name>, <string-name><surname>McDonald</surname> <given-names>EG</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Rajasingham</surname> <given-names>R</given-names></string-name>, <string-name><surname>Boulware</surname> <given-names>DR</given-names></string-name>, <year>2020</year>. <article-title>Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19</article-title>. <source>Annals of Internal Medicine</source>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Boulware</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Pullen</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Bangdiwala</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Pastick</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Lofgren</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Okafor</surname> <given-names>EC</given-names></string-name>, <string-name><surname>Skipper</surname> <given-names>CP</given-names></string-name>, <string-name><surname>Nascene</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Nicol</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Abassi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Engen</surname> <given-names>NW</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Labar</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lother</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Mackenzie</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Drobot</surname> <given-names>G</given-names></string-name>, <string-name><surname>Marten</surname> <given-names>N</given-names></string-name>, <string-name><surname>Zarychanski</surname> <given-names>R</given-names></string-name>, <string-name><surname>Kelly</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>IS</given-names></string-name>, <string-name><surname>McDonald</surname> <given-names>EG</given-names></string-name>, <string-name><surname>Rajasingham</surname> <given-names>R</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Hullsiek</surname> <given-names>KH</given-names></string-name>, <year>2020</year>. <article-title>A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19</article-title>. <source>New England Journal of Medicine</source>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><collab>RECOVERY Collaborative Group</collab>, <string-name><surname>Horby</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Mafham</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bell</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Linsell</surname> <given-names>L</given-names></string-name>, <string-name><surname>Staplin</surname> <given-names>N</given-names></string-name>, <string-name><surname>Emberson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Palfreeman</surname> <given-names>A</given-names></string-name>, <string-name><surname>Raw</surname> <given-names>J</given-names></string-name>, <string-name><surname>Elmahi</surname> <given-names>E</given-names></string-name>, <string-name><surname>Prudon</surname> <given-names>B</given-names></string-name>, <string-name><surname>Green</surname> <given-names>C</given-names></string-name>, <string-name><surname>Carley</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chadwick</surname> <given-names>D</given-names></string-name>, <string-name><surname>Davies</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wise</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Baillie</surname> <given-names>JK</given-names></string-name>, <string-name><surname>Chappell</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Faust</surname> <given-names>SN</given-names></string-name>, <string-name><surname>Jaki</surname> <given-names>T</given-names></string-name>, <string-name><surname>Jefferey</surname> <given-names>K</given-names></string-name>, <string-name><surname>Lim</surname> <given-names>WS</given-names></string-name>, <string-name><surname>Montgomery</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rowan</surname> <given-names>K</given-names></string-name>, <string-name><surname>Juszczak</surname> <given-names>E</given-names></string-name>, <string-name><surname>Haynes</surname> <given-names>R</given-names></string-name>, <string-name><surname>Landray</surname> <given-names>MJ</given-names></string-name>, <year>2020</year>. <article-title>Lopinavir&#x2013;ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial</article-title>. <source>The Lancet</source>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Abella</surname> <given-names>BS</given-names></string-name>, <string-name><surname>Jolkovsky</surname> <given-names>EL</given-names></string-name>, <string-name><surname>Biney</surname> <given-names>BT</given-names></string-name>, <string-name><surname>Uspal</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Hyman</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Frank</surname> <given-names>I</given-names></string-name>, <string-name><surname>Hensley</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Gill</surname> <given-names>S</given-names></string-name>, <string-name><surname>Vogl</surname> <given-names>DT</given-names></string-name>, <string-name><surname>Maillard</surname> <given-names>I</given-names></string-name>, <string-name><surname>Babushok</surname> <given-names>DV</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Nasta</surname> <given-names>SD</given-names></string-name>, <string-name><surname>Walsh</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Wiletyo</surname> <given-names>EP</given-names></string-name>, <string-name><surname>Gimotty</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Milone</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Amaravadi</surname> <given-names>RK</given-names></string-name>, <collab>Prevention at, Investigators ToC-WH</collab>, <year>2020</year>. <article-title>Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial</article-title>. <source>JAMA Internal Medicine</source>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Rajasingham</surname> <given-names>R</given-names></string-name>, <string-name><surname>Bangdiwala</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Nicol</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Skipper</surname> <given-names>CP</given-names></string-name>, <string-name><surname>Pastick</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Axelrod</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Pullen</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Nascene</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Williams</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Engen</surname> <given-names>NW</given-names></string-name>, <string-name><surname>Okafor</surname> <given-names>EC</given-names></string-name>, <string-name><surname>Rini</surname> <given-names>BI</given-names></string-name>, <string-name><surname>Mayer</surname> <given-names>IA</given-names></string-name>, <string-name><surname>McDonald</surname> <given-names>EG</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Li</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mackenzie</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Balko</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Dunlop</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Hullsiek</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Boulware</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Lofgren</surname> <given-names>SM</given-names></string-name>, <year>2020</year>. <article-title>Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial</article-title>. <source>Clinical Infectious Diseases</source>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Damle</surname> <given-names>B</given-names></string-name>, <string-name><surname>Vourvahis</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>E</given-names></string-name>, <string-name><surname>Leaney</surname> <given-names>J</given-names></string-name>, <string-name><surname>Corrigan</surname> <given-names>B</given-names></string-name>, <year>2020</year>. <article-title>Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19</article-title>. <source>Clinical Pharmacology &#x0026; Therapeutics</source> <volume>108</volume>: <fpage>201</fpage>&#x2013;<lpage>211</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Cavalcanti</surname> <given-names>AB</given-names></string-name>, <string-name><surname>Zampieri</surname> <given-names>FG</given-names></string-name>, <string-name><surname>Rosa</surname> <given-names>RG</given-names></string-name>, <string-name><surname>Azevedo</surname> <given-names>LCP</given-names></string-name>, <string-name><surname>Veiga</surname> <given-names>VC</given-names></string-name>, <string-name><surname>Avezum</surname> <given-names>A</given-names></string-name>, <string-name><surname>Damiani</surname> <given-names>LP</given-names></string-name>, <string-name><surname>Marcadenti</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kawano-Dourado</surname> <given-names>L</given-names></string-name>, <string-name><surname>Lisboa</surname> <given-names>T</given-names></string-name>, <string-name><surname>Junqueira</surname> <given-names>DLM</given-names></string-name>, <string-name><surname>De Barros E Silva</surname> <given-names>PGM</given-names></string-name>, <string-name><surname>Tramujas</surname> <given-names>L</given-names></string-name>, <string-name><surname>Abreu-Silva</surname> <given-names>EO</given-names></string-name>, <string-name><surname>Laranjeira</surname> <given-names>LN</given-names></string-name>, <string-name><surname>Soares</surname> <given-names>AT</given-names></string-name>, <string-name><surname>Echenique</surname> <given-names>LS</given-names></string-name>, <string-name><surname>Pereira</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Freitas</surname> <given-names>FGR</given-names></string-name>, <string-name><surname>Gebara</surname> <given-names>OCE</given-names></string-name>, <string-name><surname>Dantas</surname> <given-names>VCS</given-names></string-name>, <string-name><surname>Furtado</surname> <given-names>RHM</given-names></string-name>, <string-name><surname>Milan</surname> <given-names>EP</given-names></string-name>, <string-name><surname>Golin</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Cardoso</surname> <given-names>FF</given-names></string-name>, <string-name><surname>Maia</surname> <given-names>IS</given-names></string-name>, <string-name><surname>Hoffmann Filho</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Kormann</surname> <given-names>APM</given-names></string-name>, <string-name><surname>Amazonas</surname> <given-names>RB</given-names></string-name>, <string-name><surname>Bocchi De Oliveira</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Serpa-Neto</surname> <given-names>A</given-names></string-name>, <string-name><surname>Falavigna</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lopes</surname> <given-names>RD</given-names></string-name>, <string-name><surname>Machado</surname> <given-names>FR</given-names></string-name>, <string-name><surname>Berwanger</surname> <given-names>O</given-names></string-name>, <year>2020</year>. <article-title>Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19</article-title>. <source>New England Journal of Medicine</source> <volume>383</volume>: <fpage>2041</fpage>&#x2013;<lpage>2052</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Furtado</surname> <given-names>RHM</given-names></string-name>, <string-name><surname>Berwanger</surname> <given-names>O</given-names></string-name>, <string-name><surname>Fonseca</surname> <given-names>HA</given-names></string-name>, <string-name><surname>Corr&#x00EA;a</surname> <given-names>TD</given-names></string-name>, <string-name><surname>Ferraz</surname> <given-names>LR</given-names></string-name>, <string-name><surname>Lapa</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Zampieri</surname> <given-names>FG</given-names></string-name>, <string-name><surname>Veiga</surname> <given-names>VC</given-names></string-name>, <string-name><surname>Azevedo</surname> <given-names>LCP</given-names></string-name>, <string-name><surname>Rosa</surname> <given-names>RG</given-names></string-name>, <string-name><surname>Lopes</surname> <given-names>RD</given-names></string-name>, <string-name><surname>Avezum</surname> <given-names>A</given-names></string-name>, <string-name><surname>Manoel</surname> <given-names>ALO</given-names></string-name>, <string-name><surname>Piza</surname> <given-names>FMT</given-names></string-name>, <string-name><surname>Martins</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Lisboa</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Pereira</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Olivato</surname> <given-names>GB</given-names></string-name>, <string-name><surname>Dantas</surname> <given-names>VCS</given-names></string-name>, <string-name><surname>Milan</surname> <given-names>EP</given-names></string-name>, <string-name><surname>Gebara</surname> <given-names>OCE</given-names></string-name>, <string-name><surname>Amazonas</surname> <given-names>RB</given-names></string-name>, <string-name><surname>Oliveira</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Soares</surname> <given-names>RVP</given-names></string-name>, <string-name><surname>Moia</surname> <given-names>DDF</given-names></string-name>, <string-name><surname>Piano</surname> <given-names>LPA</given-names></string-name>, <string-name><surname>Castilho</surname> <given-names>K</given-names></string-name>, <string-name><surname>Momesso</surname> <given-names>RGRAP</given-names></string-name>, <string-name><surname>Schettino</surname> <given-names>GPP</given-names></string-name>, <string-name><surname>Rizzo</surname> <given-names>LV</given-names></string-name>, <string-name><surname>Neto</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Machado</surname> <given-names>FR</given-names></string-name>, <string-name><surname>Cavalcanti</surname> <given-names>AB</given-names></string-name>, <year>2020</year>. <article-title>Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial</article-title>. <source>The Lancet</source> <volume>396</volume>: <fpage>959</fpage>&#x2013;<lpage>967</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Kim</surname> <given-names>MS</given-names></string-name>, <string-name><surname>An</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>WJ</given-names></string-name>, <string-name><surname>Hwang</surname> <given-names>T-H</given-names></string-name>, <year>2020</year>. <article-title>Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis</article-title>. <source>PLOS Medicine</source> <volume>17</volume>: <fpage>e1003501</fpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Oldenburg</surname> <given-names>CE</given-names></string-name>, <string-name><surname>Doan</surname> <given-names>T</given-names></string-name>, <year>2020</year>. <article-title>Azithromycin for severe COVID-19</article-title>. <source>The Lancet</source> <volume>396</volume>: <fpage>936</fpage>&#x2013;<lpage>937</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Doan</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hinterwirth</surname> <given-names>A</given-names></string-name>, <string-name><surname>Arzika</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Worden</surname> <given-names>L</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zhong</surname> <given-names>L</given-names></string-name>, <string-name><surname>Oldenburg</surname> <given-names>CE</given-names></string-name>, <string-name><surname>Keenan</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Lietman</surname> <given-names>TM</given-names></string-name>, <year>2020</year>. <article-title>Reduction of Coronavirus Burden With Mass Azithromycin Distribution</article-title>. <source>Clinical Infectious Diseases</source> <volume>71</volume>: <fpage>2282</fpage>&#x2013;<lpage>2284</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Hinks</surname> <given-names>TSC</given-names></string-name>, <string-name><surname>Barber</surname> <given-names>VS</given-names></string-name>, <string-name><surname>Black</surname> <given-names>J</given-names></string-name>, <string-name><surname>Dutton</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Jabeen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Melhorn</surname> <given-names>J</given-names></string-name>, <string-name><surname>Rahman</surname> <given-names>NM</given-names></string-name>, <string-name><surname>Richards</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lasserson</surname> <given-names>D</given-names></string-name>, <string-name><surname>Pavord</surname> <given-names>ID</given-names></string-name>, <string-name><surname>Bafadhel</surname> <given-names>M</given-names></string-name>, <year>2020</year>. <article-title>A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial</article-title>. <source>Trials</source> <volume>21</volume>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Poustchi</surname> <given-names>H</given-names></string-name>, <string-name><surname>Majd Jabbari</surname> <given-names>S</given-names></string-name>, <string-name><surname>Merat</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sharifi</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Shayesteh</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Shayesteh</surname> <given-names>E</given-names></string-name>, <string-name><surname>Minakari</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fattahi</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Moini</surname> <given-names>M</given-names></string-name>, <string-name><surname>Roozbeh</surname> <given-names>F</given-names></string-name>, <string-name><surname>Mansour-Ghanaei</surname> <given-names>F</given-names></string-name>, <string-name><surname>Afshar</surname> <given-names>B</given-names></string-name>, <string-name><surname>Mokhtare</surname> <given-names>M</given-names></string-name>, <string-name><surname>Amiriani</surname> <given-names>T</given-names></string-name>, <string-name><surname>Sofian</surname> <given-names>M</given-names></string-name>, <string-name><surname>Somi</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Agah</surname> <given-names>S</given-names></string-name>, <string-name><surname>Maleki</surname> <given-names>I</given-names></string-name>, <string-name><surname>Latifnia</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fattahi Abdizadeh</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hormati</surname> <given-names>A</given-names></string-name>, <string-name><surname>Khoshnia</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sohrabi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Malekzadeh</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Merat</surname> <given-names>D</given-names></string-name>, <string-name><surname>Malekzadeh</surname> <given-names>R</given-names></string-name>, <year>2020</year>. <article-title>The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment</article-title>. <source>J Gastroenterol Hepatol</source>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Gao</surname> <given-names>L</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Duan</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mao</surname> <given-names>C</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>D</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>W</given-names></string-name>, <string-name><surname>Nie</surname> <given-names>J</given-names></string-name>, <string-name><surname>Hou</surname> <given-names>Y</given-names></string-name>, <year>2010</year>. <article-title>A randomized controlled trial of low-dose recombinant human interferons &#x03B1;-2b nasal spray to prevent acute viral respiratory infections in military recruits</article-title>. <source>Vaccine</source> <volume>28</volume>: <fpage>4445</fpage>&#x2013;<lpage>4451</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Jiang</surname> <given-names>H-w</given-names></string-name>, <string-name><given-names>Zhang</given-names> <surname>H-n</surname></string-name>, <string-name><given-names>Meng</given-names> <surname>Q-f</surname></string-name>, <string-name><surname>Xie</surname> <given-names>J</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>Y-x</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X-n</given-names></string-name>, <string-name><surname>Qi</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>P-H</given-names></string-name>, <string-name><surname>Han</surname> <given-names>Z-G</given-names></string-name>, <string-name><surname>Tao</surname> <given-names>S-c</given-names></string-name>, <year>2020</year>. <article-title>SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70</article-title>. <source>Cellular &#x0026; Molecular Immunology</source> <volume>17</volume>: <fpage>998</fpage>&#x2013;<lpage>1000</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Clementi</surname> <given-names>N</given-names></string-name>, <string-name><surname>Ferrarese</surname> <given-names>R</given-names></string-name>, <string-name><surname>Criscuolo</surname> <given-names>E</given-names></string-name>, <string-name><surname>Diotti</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Castelli</surname> <given-names>M</given-names></string-name>, <string-name><surname>Scagnolari</surname> <given-names>C</given-names></string-name>, <string-name><surname>Burioni</surname> <given-names>R</given-names></string-name>, <string-name><surname>Antonelli</surname> <given-names>G</given-names></string-name>, <string-name><surname>Clementi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mancini</surname> <given-names>N</given-names></string-name>, <year>2020</year>. <article-title>Interferon-&#x03B2;-1a Inhibition of Severe Acute Respiratory Syndrome&#x2013;Coronavirus 2 In Vitro When Administered After Virus Infection</article-title>. <source>The Journal of Infectious Diseases</source>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Hung</surname> <given-names>IF-N</given-names></string-name>, <string-name><surname>Lung</surname> <given-names>K-C</given-names></string-name>, <string-name><given-names>Tso</given-names> <surname>EY-K</surname></string-name>, <string-name><surname>Liu</surname> <given-names>R</given-names></string-name>, <string-name><surname>Chung</surname> <given-names>TW-H</given-names></string-name>, <string-name><surname>Chu</surname> <given-names>M-Y</given-names></string-name>, <string-name><surname>Ng</surname> <given-names>Y-Y</given-names></string-name>, <string-name><surname>Lo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Tam</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Shum</surname> <given-names>H-P</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>V</given-names></string-name>, <string-name><given-names>Wu</given-names> <surname>AK-L</surname></string-name>, <string-name><surname>Sin</surname> <given-names>K-M</given-names></string-name>, <string-name><surname>Leung</surname> <given-names>W-S</given-names></string-name>, <string-name><surname>Law</surname> <given-names>W-L</given-names></string-name>, <string-name><surname>Lung</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Sin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Yeung</surname> <given-names>P</given-names></string-name>, <string-name><surname>Yip</surname> <given-names>CC-Y</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>RR</given-names></string-name>, <string-name><surname>Fung</surname> <given-names>AY-F</given-names></string-name>, <string-name><given-names>Yan</given-names> <surname>EY-W</surname></string-name>, <string-name><surname>Leung</surname> <given-names>K-H</given-names></string-name>, <string-name><surname>Ip</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Chu</surname> <given-names>AW-H</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>W-M</given-names></string-name>, <string-name><given-names>Ng</given-names> <surname>AC-K</surname></string-name>, <string-name><surname>Lee</surname> <given-names>R</given-names></string-name>, <string-name><surname>Fung</surname> <given-names>K</given-names></string-name>, <string-name><surname>Yeung</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>T-C</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>JW-M</given-names></string-name>, <string-name><surname>Yan</surname> <given-names>W-W</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>W-M</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>JF-W</given-names></string-name>, <string-name><surname>Lie</surname> <given-names>AK-W</given-names></string-name>, <string-name><surname>Tsang</surname> <given-names>OT-Y</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>VC-C</given-names></string-name>, <string-name><surname>Que</surname> <given-names>T-L</given-names></string-name>, <string-name><surname>Lau</surname> <given-names>C-S</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>K-H</given-names></string-name>, <string-name><given-names>To</given-names> <surname>KK-W</surname></string-name>, <string-name><surname>Yuen</surname> <given-names>K-Y</given-names></string-name>, <year>2020</year>. <article-title>Triple combination of interferon beta-1b, lopinavir&#x2013;ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial</article-title>. <source>The Lancet</source> <volume>395</volume>: <fpage>1695</fpage>&#x2013;<lpage>1704</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Davoudi-Monfared</surname> <given-names>E</given-names></string-name>, <string-name><surname>Rahmani</surname> <given-names>H</given-names></string-name>, <string-name><surname>Khalili</surname> <given-names>H</given-names></string-name>, <string-name><surname>Hajiabdolbaghi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Salehi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Abbasian</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kazemzadeh</surname> <given-names>H</given-names></string-name>, <string-name><surname>Yekaninejad</surname> <given-names>MS</given-names></string-name>, <year>2020</year>. <article-title>A Randomized Clinical Trial of the Efficacy and Safety of Interferon &#x03B2;-1a in Treatment of Severe COVID-19</article-title>. <source>Antimicrobial Agents and Chemotherapy</source> <volume>64</volume>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Cao</surname> <given-names>B</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wen</surname> <given-names>D</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>W</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Fan</surname> <given-names>G</given-names></string-name>, <string-name><surname>Ruan</surname> <given-names>L</given-names></string-name>, <string-name><surname>Song</surname> <given-names>B</given-names></string-name>, <string-name><surname>Cai</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>M</given-names></string-name>, <string-name><surname>Li</surname> <given-names>X</given-names></string-name>, <string-name><surname>Xia</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>N</given-names></string-name>, <string-name><surname>Xiang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>T</given-names></string-name>, <string-name><surname>Bai</surname> <given-names>T</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Li</surname> <given-names>C</given-names></string-name>, <string-name><surname>Yuan</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>H</given-names></string-name>, <string-name><surname>Li</surname> <given-names>H</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Tu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gong</surname> <given-names>F</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Dong</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>F</given-names></string-name>, <string-name><surname>Gu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Li</surname> <given-names>H</given-names></string-name>, <string-name><surname>Shang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>K</given-names></string-name>, <string-name><surname>Li</surname> <given-names>K</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>X</given-names></string-name>, <string-name><surname>Dong</surname> <given-names>X</given-names></string-name>, <string-name><surname>Qu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Ruan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Peng</surname> <given-names>L</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>F</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>L</given-names></string-name>, <string-name><surname>Zou</surname> <given-names>J</given-names></string-name>, <string-name><surname>Jia</surname> <given-names>C</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Ge</surname> <given-names>Q</given-names></string-name>, <string-name><surname>He</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhan</surname> <given-names>H</given-names></string-name>, <string-name><surname>Qiu</surname> <given-names>F</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>L</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Jaki</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hayden</surname> <given-names>FG</given-names></string-name>, <string-name><surname>Horby</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>C</given-names></string-name>, <year>2020</year>. <article-title>A Trial of Lopinavir&#x2013;Ritonavir in Adults Hospitalized with Severe Covid-19</article-title>. <source>New England Journal of Medicine</source> <volume>382</volume>: <fpage>1787</fpage>&#x2013;<lpage>1799</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Cai</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>M</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>D</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>J</given-names></string-name>, <string-name><surname>Shu</surname> <given-names>D</given-names></string-name>, <string-name><surname>Xia</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Gu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Cai</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>C</given-names></string-name>, <string-name><surname>Li</surname> <given-names>X</given-names></string-name>, <string-name><surname>Peng</surname> <given-names>L</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>F</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>L</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Cao</surname> <given-names>R</given-names></string-name>, <string-name><surname>Zhong</surname> <given-names>W</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>L</given-names></string-name>, <year>2020</year>. <article-title>Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study</article-title>. <source>Engineering</source>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Coomes</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Haghbayan</surname> <given-names>H</given-names></string-name>, <year>2020</year>. <article-title>Favipiravir, an antiviral for COVID-19?</article-title> <source>Journal of Antimicrobial Chemotherapy</source> <volume>75</volume>: <fpage>2013</fpage>&#x2013;<lpage>2014</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Smither</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Eastaugh</surname> <given-names>LS</given-names></string-name>, <string-name><surname>Steward</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Nelson</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lenk</surname> <given-names>RP</given-names></string-name>, <string-name><surname>Lever</surname> <given-names>MS</given-names></string-name>, <year>2014</year>. <article-title>Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model</article-title>. <source>Antiviral Res</source> <volume>104</volume>: <fpage>153</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="other"><collab>Glenmark Pharmaceuticals L</collab>, <year>2020</year>. <article-title>Glenmark Announces Top-Line Results From Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19</article-title>. <source>Phase 3 Trial Demonstrates Statistically Significant Faster Time to Clinical Improvement with Favipiravir Treatment in Mild to Moderate COVID 19 Patients Compared to Control</source>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Caly</surname> <given-names>L</given-names></string-name>, <string-name><surname>Druce</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Catton</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Jans</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Wagstaff</surname> <given-names>KM</given-names></string-name>, <year>2020</year>. <article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</article-title>. <source>Antiviral Research</source> <volume>178</volume>: <fpage>104787</fpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Schmith</surname> <given-names>VD</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lohmer</surname> <given-names>LRL</given-names></string-name>, <year>2020</year>. <article-title>The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19</article-title>. <source>Clinical Pharmacology &#x0026; Therapeutics</source>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Konecny</surname> <given-names>P</given-names></string-name>, <string-name><surname>Weatherall</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Adhikari</surname> <given-names>S</given-names></string-name>, <string-name><surname>Duflou</surname> <given-names>J</given-names></string-name>, <string-name><surname>Marjoniemi</surname> <given-names>V</given-names></string-name>, <string-name><surname>Pretorius</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>McWhinney</surname> <given-names>B</given-names></string-name>, <year>2018</year>. <article-title>Case Report: Subcutaneous Ivermectin Pharmacokinetics in Disseminated Strongyloides Infection: Plasma and Postmortem Analysis</article-title>. <source>The American journal of tropical medicine and hygiene</source> <volume>99</volume>: <fpage>1580</fpage>&#x2013;<lpage>1582</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="other"><string-name><surname>Mahmud</surname> <given-names>R</given-names></string-name>, <year>2020</year>. <source>Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection</source>. Available at: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04523831">https://clinicaltrials.gov/ct2/show/NCT04523831</ext-link>. Accessed <date-in-citation content-type="access-date">22 Oct, 2020</date-in-citation>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Stauffer</surname> <given-names>WM</given-names></string-name>, <string-name><surname>Alpern</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Walker</surname> <given-names>PF</given-names></string-name>, <year>2020</year>. <article-title>COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection</article-title>. <source>JAMA</source>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Rossignol</surname> <given-names>J-F</given-names></string-name>, <year>2016</year>. <article-title>Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus</article-title>. <source>Journal of Infection and Public Health</source> <volume>9</volume>: <fpage>227</fpage>&#x2013;<lpage>230</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Haffizulla</surname> <given-names>J</given-names></string-name>, <string-name><surname>Hartman</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hoppers</surname> <given-names>M</given-names></string-name>, <string-name><surname>Resnick</surname> <given-names>H</given-names></string-name>, <string-name><surname>Samudrala</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ginocchio</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bardin</surname> <given-names>M</given-names></string-name>, <string-name><surname>Rossignol</surname> <given-names>J-F</given-names></string-name>, <year>2014</year>. <article-title>Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial</article-title>. <source>The Lancet Infectious Diseases</source> <volume>14</volume>: <fpage>609</fpage>&#x2013;<lpage>618</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Gami&#x00F1;o-Arroyo</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Guerrero</surname> <given-names>ML</given-names></string-name>, <string-name><surname>McCarthy</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ram&#x00ED;rez-Venegas</surname> <given-names>A</given-names></string-name>, <string-name><surname>Llamosas-Gallardo</surname> <given-names>B</given-names></string-name>, <string-name><surname>Galindo-Fraga</surname> <given-names>A</given-names></string-name>, <string-name><surname>Moreno-Espinosa</surname> <given-names>S</given-names></string-name>, <string-name><surname>Rold&#x00E1;n-Arag&#x00F3;n</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Araujo-Mel&#x00E9;ndez</surname> <given-names>J</given-names></string-name>, <string-name><surname>Hunsberger</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ibarra-Gonz&#x00E1;lez</surname> <given-names>V</given-names></string-name>, <string-name><surname>Mart&#x00ED;nez-L&#x00F3;pez</surname> <given-names>J</given-names></string-name>, <string-name><surname>Garc&#x00ED;a-Andrade</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Kapushoc</surname> <given-names>H</given-names></string-name>, <string-name><surname>Holley</surname> <given-names>HP</given-names></string-name>, <string-name><surname>Smolskis</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Ruiz-Palacios</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Beigel</surname> <given-names>JH</given-names></string-name>, <collab>Mexico Emerging Infectious Diseases Clinical Research N</collab>, <year>2019</year>. <article-title>Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness</article-title>. <source>Clinical Infectious Diseases</source> <volume>69</volume>: <fpage>1903</fpage>&#x2013;<lpage>1911</lpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Pepperrell</surname> <given-names>T</given-names></string-name>, <string-name><surname>Pilkington</surname> <given-names>V</given-names></string-name>, <string-name><surname>Owen</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Hill</surname> <given-names>AM</given-names></string-name>, <year>2020</year>. <article-title>Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19</article-title>. <source>Journal of virus eradication</source> <volume>6</volume>: <fpage>52</fpage>&#x2013;<lpage>60</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Rocco PRM</surname> <given-names>SP</given-names></string-name>, <string-name><surname>Cruz</surname> <given-names>FF</given-names></string-name>, <year>2020</year>. <article-title>Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial</article-title>. <source>medRxiv</source>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Sanders</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Monogue</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Jodlowski</surname> <given-names>TZ</given-names></string-name>, <string-name><surname>Cutrell</surname> <given-names>JB</given-names></string-name>, <year>2020</year>. <article-title>Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)</article-title>. <source>JAMA</source>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Stopsack</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Mucci</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Antonarakis</surname> <given-names>ES</given-names></string-name>, <string-name><surname>Nelson</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Kantoff</surname> <given-names>PW</given-names></string-name>, <year>2020</year>. <article-title>TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?</article-title> <source>Cancer Discovery</source> <volume>10</volume>: <fpage>779</fpage>&#x2013;<lpage>782</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Hoffmann</surname> <given-names>M</given-names></string-name>, <string-name><surname>Schroeder</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kleine-Weber</surname> <given-names>H</given-names></string-name>, <string-name><surname>M&#x00FC;ller</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Drosten</surname> <given-names>C</given-names></string-name>, <string-name><surname>P&#x00F6;hlmann</surname> <given-names>S</given-names></string-name>, <year>2020</year>. <article-title>Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19</article-title>. <source>Antimicrobial Agents and Chemotherapy</source>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname> <given-names>T</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>C</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>D</given-names></string-name>, <string-name><surname>Dai</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Bao</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>X</given-names></string-name>, <year>2020</year>. <article-title>Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study</article-title>. <source>Clin Transl Sci</source> <volume>13</volume>: <fpage>1096</fpage>&#x2013;<lpage>1102</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Maggio</surname> <given-names>R</given-names></string-name>, <string-name><surname>Corsini</surname> <given-names>GU</given-names></string-name>, <year>2020</year>. <article-title>Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection</article-title>. <source>Pharmacol Res</source> <volume>157</volume>: <fpage>104837</fpage>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="other"><collab>WHO</collab>, <year>2019</year>. <source>The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (i ncluding the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children)</source>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Pindiprolu</surname> <given-names>SKSS</given-names></string-name>, <string-name><surname>Pindiprolu</surname> <given-names>SH</given-names></string-name>, <year>2020</year>. <article-title>Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19</article-title>. <source>Medical Hypotheses</source> <volume>140</volume>: <fpage>109765</fpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Lian</surname> <given-names>N</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>H</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>Q</given-names></string-name>, <year>2020</year>. <article-title>Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study</article-title>. <source>Clinical Microbiology and Infection</source> <volume>26</volume>: <fpage>917</fpage>&#x2013;<lpage>921</lpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Huang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>H</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>T</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Yao</surname> <given-names>R</given-names></string-name>, <string-name><surname>Liang</surname> <given-names>Z</given-names></string-name>, <year>2020</year>. <article-title>Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis</article-title>. <source>Journal of Medical Virology</source>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Pol</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bourliere</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lucier</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hezode</surname> <given-names>C</given-names></string-name>, <string-name><surname>Dorival</surname> <given-names>C</given-names></string-name>, <string-name><surname>Larrey</surname> <given-names>D</given-names></string-name>, <string-name><surname>Bronowicki</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Ledinghen</surname> <given-names>VD</given-names></string-name>, <string-name><surname>Zoulim</surname> <given-names>F</given-names></string-name>, <string-name><surname>Tran</surname> <given-names>A</given-names></string-name>, <string-name><surname>Metivier</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zarski</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Samuel</surname> <given-names>D</given-names></string-name>, <string-name><surname>Guyader</surname> <given-names>D</given-names></string-name>, <string-name><surname>Marcellin</surname> <given-names>P</given-names></string-name>, <string-name><surname>Minello</surname> <given-names>A</given-names></string-name>, <string-name><surname>Alric</surname> <given-names>L</given-names></string-name>, <string-name><surname>Thabut</surname> <given-names>D</given-names></string-name>, <string-name><surname>Chazouilleres</surname> <given-names>O</given-names></string-name>, <string-name><surname>Riachi</surname> <given-names>G</given-names></string-name>, <string-name><surname>Bourcier</surname> <given-names>V</given-names></string-name>, <string-name><surname>Mathurin</surname> <given-names>P</given-names></string-name>, <string-name><surname>Loustaud-Ratti</surname> <given-names>V</given-names></string-name>, <string-name><surname>D&#x2019;Alteroche</surname> <given-names>L</given-names></string-name>, <string-name><surname>Fouchard-Hubert</surname> <given-names>I</given-names></string-name>, <string-name><surname>Habersetzer</surname> <given-names>F</given-names></string-name>, <string-name><surname>Causse</surname> <given-names>X</given-names></string-name>, <string-name><surname>Geist</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rosa</surname> <given-names>I</given-names></string-name>, <string-name><surname>Gournay</surname> <given-names>J</given-names></string-name>, <string-name><surname>Saillard</surname> <given-names>E</given-names></string-name>, <string-name><surname>Billaud</surname> <given-names>E</given-names></string-name>, <string-name><surname>Petrov-Sanchez</surname> <given-names>V</given-names></string-name>, <string-name><surname>Diallo</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fontaine</surname> <given-names>H</given-names></string-name>, <string-name><surname>Carrat</surname> <given-names>F</given-names></string-name>, <year>2017</year>. <article-title>Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients</article-title>. <source>J Hepatol</source> <volume>66</volume>: <fpage>39</fpage>&#x2013;<lpage>47</lpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Ahmed</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mahtarin</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ahmed</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Akter</surname> <given-names>S</given-names></string-name>, <string-name><surname>Islam</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Mamun</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Islam</surname> <given-names>R</given-names></string-name>, <string-name><surname>Hossain</surname> <given-names>MN</given-names></string-name>, <string-name><surname>Ali</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Sultana</surname> <given-names>MUC</given-names></string-name>, <string-name><surname>Parves</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Ullah</surname> <given-names>MO</given-names></string-name>, <string-name><surname>Halim</surname> <given-names>MA</given-names></string-name>, <year>2020</year>. <article-title>Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2</article-title>. <source>J Biomol Struct Dyn</source>: <fpage>1</fpage>&#x2013;<lpage>16</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Shah</surname> <given-names>B</given-names></string-name>, <string-name><surname>Modi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Sagar</surname> <given-names>SR</given-names></string-name>, <year>2020</year>. <article-title>In silico studies on therapeutic agents for COVID-19: Drug repurposing approach</article-title>. <source>Life sciences</source> <volume>252</volume>: <fpage>117652</fpage>&#x2013;<lpage>117652</lpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Elfiky</surname> <given-names>AA</given-names></string-name>, <year>2020</year>. <article-title>Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study</article-title>. <source>Life Sciences</source> <volume>253</volume>: <fpage>117592</fpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Abbaspour Kasgari</surname> <given-names>H</given-names></string-name>, <string-name><surname>Moradi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shabani</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Babamahmoodi</surname> <given-names>F</given-names></string-name>, <string-name><surname>Davoudi Badabi</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Davoudi</surname> <given-names>L</given-names></string-name>, <string-name><surname>Alikhani</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hedayatizadeh Omran</surname> <given-names>A</given-names></string-name>, <string-name><surname>Saeedi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Merat</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wentzel</surname> <given-names>H</given-names></string-name>, <string-name><surname>Garratt</surname> <given-names>A</given-names></string-name>, <string-name><surname>Levi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Simmons</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hill</surname> <given-names>A</given-names></string-name>, <string-name><given-names>Tirgar</given-names> <surname>Fakheri</surname></string-name> H, <year>2020</year>. <article-title>Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial</article-title>. <source>J Antimicrob Chemother</source> <volume>75</volume>: <fpage>3373</fpage>&#x2013;<lpage>3378</lpage>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Eslami</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mousaviasl</surname> <given-names>S</given-names></string-name>, <string-name><surname>Radmanesh</surname> <given-names>E</given-names></string-name>, <string-name><surname>Jelvay</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bitaraf</surname> <given-names>S</given-names></string-name>, <string-name><surname>Simmons</surname> <given-names>B</given-names></string-name>, <string-name><surname>Wentzel</surname> <given-names>H</given-names></string-name>, <string-name><surname>Hill</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sadeghi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Freeman</surname> <given-names>J</given-names></string-name>, <string-name><surname>Salmanzadeh</surname> <given-names>S</given-names></string-name>, <string-name><surname>Esmaeilian</surname> <given-names>H</given-names></string-name>, <string-name><surname>Mobarak</surname> <given-names>M</given-names></string-name>, <string-name><surname>Tabibi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Jafari Kashi</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Lotfi</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Talebzadeh</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Wickramatillake</surname> <given-names>A</given-names></string-name>, <string-name><surname>Momtazan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hajizadeh Farsani</surname> <given-names>M</given-names></string-name>, <string-name><surname>Marjani</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mobarak</surname> <given-names>S</given-names></string-name>, <year>2020</year>. <article-title>The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19</article-title>. <source>J Antimicrob Chemother</source> <volume>75</volume>: <fpage>3366</fpage>&#x2013;<lpage>3372</lpage>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Sadeghi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ali Asgari</surname> <given-names>A</given-names></string-name>, <string-name><surname>Norouzi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kheiri</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Anushirvani</surname> <given-names>A</given-names></string-name>, <string-name><surname>Montazeri</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hosamirudsai</surname> <given-names>H</given-names></string-name>, <string-name><surname>Afhami</surname> <given-names>S</given-names></string-name>, <string-name><surname>Akbarpour</surname> <given-names>E</given-names></string-name>, <string-name><surname>Aliannejad</surname> <given-names>R</given-names></string-name>, <string-name><surname>Radmard</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Davarpanah</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Levi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wentzel</surname> <given-names>H</given-names></string-name>, <string-name><surname>Qavi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Garratt</surname> <given-names>A</given-names></string-name>, <string-name><surname>Simmons</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hill</surname> <given-names>A</given-names></string-name>, <string-name><surname>Merat</surname> <given-names>S</given-names></string-name>, <year>2020</year>. <article-title>Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial</article-title>. <source>J Antimicrob Chemother</source> <volume>75</volume>: <fpage>3379</fpage>&#x2013;<lpage>3385</lpage>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Urakova</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kuznetsova</surname> <given-names>V</given-names></string-name>, <string-name><surname>Crossman</surname> <given-names>DK</given-names></string-name>, <string-name><surname>Sokratian</surname> <given-names>A</given-names></string-name>, <string-name><surname>Guthrie</surname> <given-names>DB</given-names></string-name>, <string-name><surname>Kolykhalov</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Lockwood</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Natchus</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Crowley</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Painter</surname> <given-names>GR</given-names></string-name>, <string-name><surname>Frolova</surname> <given-names>EI</given-names></string-name>, <string-name><surname>Frolov</surname> <given-names>I</given-names></string-name>, <year>2018</year>. <article-title>&#x03B2;-d-N (4)-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome</article-title>. <source>J Virol</source> <volume>92</volume>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Sheahan</surname> <given-names>TP</given-names></string-name>, <string-name><surname>Sims</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>S</given-names></string-name>, <string-name><surname>Graham</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Pruijssers</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Agostini</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Leist</surname> <given-names>SR</given-names></string-name>, <string-name><surname>Sch&#x00E4;fer</surname> <given-names>A</given-names></string-name>, <string-name><surname>Dinnon</surname> <given-names>KH</given-names></string-name>, 3rd, <string-name><surname>Stevens</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Chappell</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Hughes</surname> <given-names>TM</given-names></string-name>, <string-name><surname>George</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Hill</surname> <given-names>CS</given-names></string-name>, <string-name><surname>Montgomery</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Brown</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Bluemling</surname> <given-names>GR</given-names></string-name>, <string-name><surname>Natchus</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Saindane</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kolykhalov</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Painter</surname> <given-names>G</given-names></string-name>, <string-name><surname>Harcourt</surname> <given-names>J</given-names></string-name>, <string-name><surname>Tamin</surname> <given-names>A</given-names></string-name>, <string-name><surname>Thornburg</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Swanstrom</surname> <given-names>R</given-names></string-name>, <string-name><surname>Denison</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Baric</surname> <given-names>RS</given-names></string-name>, <year>2020</year>. <article-title>An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice</article-title>. <source>Sci Transl Med</source> <volume>12</volume>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Slaoui</surname> <given-names>M</given-names></string-name>, <string-name><surname>Greene</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Woodcock</surname> <given-names>J</given-names></string-name>, <year>2020</year>. <article-title>Bridging the Gap at Warp Speed &#x2014; Delivering Options for Preventing and Treating Covid-19</article-title>. <source>New England Journal of Medicine</source>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Meertens</surname> <given-names>L</given-names></string-name>, <string-name><surname>Labeau</surname> <given-names>A</given-names></string-name>, <string-name><surname>Dejarnac</surname> <given-names>O</given-names></string-name>, <string-name><surname>Cipriani</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sinigaglia</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bonnet-Madin</surname> <given-names>L</given-names></string-name>, <string-name><surname>Le Charpentier</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hafirassou</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Zamborlini</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cao-Lormeau</surname> <given-names>V-M</given-names></string-name>, <string-name><surname>Coulpier</surname> <given-names>M</given-names></string-name>, <string-name><surname>Miss&#x00E9;</surname> <given-names>D</given-names></string-name>, <string-name><surname>Jouvenet</surname> <given-names>N</given-names></string-name>, <string-name><surname>Tabibiazar</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gressens</surname> <given-names>P</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>O</given-names></string-name>, <string-name><surname>Amara</surname> <given-names>A</given-names></string-name>, <year>2017</year>. <article-title>Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses</article-title>. <source>Cell Reports</source> <volume>18</volume>: <fpage>324</fpage>&#x2013;<lpage>333</lpage>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>Encinar</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Menendez</surname> <given-names>JA</given-names></string-name>, <year>2020</year>. <article-title>Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2&#x2019;-O-Methylation of Viral RNA</article-title>. <source>Viruses</source> <volume>12</volume>: <fpage>525</fpage>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><string-name><surname>Halin</surname> <given-names>C</given-names></string-name>, <string-name><surname>Scimone</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Bonasio</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gauguet</surname> <given-names>J-M</given-names></string-name>, <string-name><surname>Mempel</surname> <given-names>TR</given-names></string-name>, <string-name><surname>Quackenbush</surname> <given-names>E</given-names></string-name>, <string-name><surname>Proia</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Mandala</surname> <given-names>S</given-names></string-name>, <string-name><surname>von Andrian</surname> <given-names>UH</given-names></string-name>, <year>2005</year>. <article-title>The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell&#x2013;expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches</article-title>. <source>Blood</source> <volume>106</volume>: <fpage>1314</fpage>&#x2013;<lpage>1322</lpage>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><string-name><surname>Kappos</surname> <given-names>L</given-names></string-name>, <string-name><surname>Radue</surname> <given-names>E-W</given-names></string-name>, <string-name><surname>O&#x2019;Connor</surname> <given-names>P</given-names></string-name>, <string-name><surname>Polman</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hohlfeld</surname> <given-names>R</given-names></string-name>, <string-name><surname>Calabresi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Selmaj</surname> <given-names>K</given-names></string-name>, <string-name><surname>Agoropoulou</surname> <given-names>C</given-names></string-name>, <string-name><surname>Leyk</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zhang-Auberson</surname> <given-names>L</given-names></string-name>, <year>2010</year>. <article-title>A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis</article-title>. <source>New England Journal of Medicine</source> <volume>362</volume>: <fpage>387</fpage>&#x2013;<lpage>401</lpage>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><string-name><surname>Massberg</surname> <given-names>S</given-names></string-name>, <string-name><surname>von Andrian</surname> <given-names>UH</given-names></string-name>, <year>2006</year>. <article-title>Fingolimod and sphingosine-1-phosphate&#x2014;modifiers of lymphocyte migration</article-title>. <source>New England Journal of Medicine</source> <volume>355</volume>: <fpage>1088</fpage>&#x2013;<lpage>1091</lpage>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><string-name><surname>Pinschewer</surname> <given-names>DD</given-names></string-name>, <string-name><surname>Brinkmann</surname> <given-names>V</given-names></string-name>, <string-name><surname>Merkler</surname> <given-names>D</given-names></string-name>, <year>2011</year>. <article-title>Impact of sphingosine 1-phosphate modulation on immune outcomes</article-title>. <source>Neurology</source> <volume>76</volume>: <fpage>S15</fpage>&#x2013;<lpage>S19</lpage>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><string-name><surname>Valencia-Sanchez</surname> <given-names>C</given-names></string-name>, <string-name><surname>Wingerchuk</surname> <given-names>DM</given-names></string-name>, <year>2020</year>. <article-title>A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19</article-title>. <source>Multiple Sclerosis and Related Disorders</source>: <fpage>102182</fpage>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><string-name><surname>Foerch</surname> <given-names>C</given-names></string-name>, <string-name><surname>Friedauer</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bauer</surname> <given-names>B</given-names></string-name>, <string-name><surname>Wolf</surname> <given-names>T</given-names></string-name>, <string-name><surname>Adam</surname> <given-names>EH</given-names></string-name>, <year>2020</year>. <article-title>Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod</article-title>. <source>Multiple Sclerosis and Related Disorders</source>: <fpage>102180</fpage>.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><string-name><surname>Natarajan</surname> <given-names>V</given-names></string-name>, <string-name><surname>Dudek</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Jacobson</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Moreno-Vinasco</surname> <given-names>L</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>LS</given-names></string-name>, <string-name><surname>Abassi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mathew</surname> <given-names>B</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bittman</surname> <given-names>R</given-names></string-name>, <year>2013</year>. <article-title>Sphingosine-1&#x2013;phosphate, FTY720, and Sphingosine-1&#x2013; phosphate receptors in the pathobiology of acute lung injury</article-title>. <source>American journal of respiratory cell and molecular biology</source> <volume>49</volume>: <fpage>6</fpage>&#x2013;<lpage>17</lpage>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><string-name><surname>Lisi</surname> <given-names>L</given-names></string-name>, <string-name><surname>Lacal</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Barbaccia</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Graziani</surname> <given-names>G</given-names></string-name>, <year>2020</year>. <article-title>Approaching coronavirus disease 2019 Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2</article-title>. <source>Biochemical pharmacology</source>: <fpage>114169</fpage>.</mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><string-name><surname>Wynants</surname> <given-names>L</given-names></string-name>, <string-name><surname>Van Calster</surname> <given-names>B</given-names></string-name>, <string-name><surname>Collins</surname> <given-names>GS</given-names></string-name>, <string-name><surname>Riley</surname> <given-names>RD</given-names></string-name>, <string-name><surname>Heinze</surname> <given-names>G</given-names></string-name>, <string-name><surname>Schuit</surname> <given-names>E</given-names></string-name>, <string-name><surname>Bonten</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Dahly</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Damen</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Debray</surname> <given-names>TP</given-names></string-name>, <year>2020</year>. <article-title>Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal</article-title>. <source>bmj</source> <volume>369</volume>.</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="other"><string-name><surname>Yatomi</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ruan</surname> <given-names>F</given-names></string-name>, <string-name><surname>Hakomori</surname> <given-names>S-i</given-names></string-name>, <string-name><surname>Igarashi</surname> <given-names>Y</given-names></string-name>, <year>1995</year>. <source>Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets</source>.</mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><string-name><surname>Prieschl</surname> <given-names>EE</given-names></string-name>, <string-name><surname>Csonga</surname> <given-names>R</given-names></string-name>, <string-name><surname>Novotny</surname> <given-names>V</given-names></string-name>, <string-name><surname>Kikuchi</surname> <given-names>GE</given-names></string-name>, <string-name><surname>Baumruker</surname> <given-names>T</given-names></string-name>, <year>1999</year>. <article-title>The Balance between Sphingosine and Sphingosine-1-Phosphate Is Decisive for Mast Cell Activation after Fc&#x2208; Receptor I Triggering</article-title>. <source>The Journal of experimental medicine</source> <volume>190</volume>: <fpage>1</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><string-name><surname>Pettus</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Bielawski</surname> <given-names>J</given-names></string-name>, <string-name><surname>Porcelli</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Reames</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Morrow</surname> <given-names>&#x2208;J</given-names></string-name>, <string-name><surname>Chalfant</surname> <given-names>CE</given-names></string-name>, <string-name><surname>Obeid</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Hannun</surname> <given-names>YA</given-names></string-name>, <year>2003</year>. <article-title>The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-&#x03B1;</article-title>. <source>The FASEB Journal</source> <volume>17</volume>: <fpage>1411</fpage>&#x2013;<lpage>1421</lpage>.</mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="journal"><string-name><surname>Maines</surname> <given-names>LW</given-names></string-name>, <string-name><surname>Fitzpatrick</surname> <given-names>LR</given-names></string-name>, <string-name><surname>French</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Zhuang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Xia</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Keller</surname> <given-names>SN</given-names></string-name>, <string-name><surname>Upson</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>CD</given-names></string-name>, <year>2008</year>. <article-title>Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase</article-title>. <source>Digestive diseases and sciences</source> <volume>53</volume>: <fpage>997</fpage>&#x2013;<lpage>1012</lpage>.</mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><string-name><surname>Ebenezer</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Berdyshev</surname> <given-names>EV</given-names></string-name>, <string-name><surname>Bronova</surname> <given-names>IA</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Tiruppathi</surname> <given-names>C</given-names></string-name>, <string-name><surname>Komarova</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Benevolenskaya</surname> <given-names>EV</given-names></string-name>, <string-name><surname>Suryadevara</surname> <given-names>V</given-names></string-name>, <string-name><surname>Ha</surname> <given-names>AW</given-names></string-name>, <string-name><surname>Harijith</surname> <given-names>A</given-names></string-name>, <year>2019</year>. <article-title>Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury</article-title>. <source>Thorax</source> <volume>74</volume>: <fpage>579</fpage>&#x2013;<lpage>591</lpage>.</mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><string-name><surname>Reid</surname> <given-names>SP</given-names></string-name>, <string-name><surname>Tritsch</surname> <given-names>SR</given-names></string-name>, <string-name><surname>Kota</surname> <given-names>K</given-names></string-name>, <string-name><surname>Chiang</surname> <given-names>C-Y</given-names></string-name>, <string-name><surname>Dong</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kenny</surname> <given-names>T</given-names></string-name>, <string-name><surname>Brueggemann</surname> <given-names>EE</given-names></string-name>, <string-name><surname>Ward</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Cazares</surname> <given-names>LH</given-names></string-name>, <string-name><surname>Bavari</surname> <given-names>S</given-names></string-name>, <year>2015</year>. <article-title>Sphingosine kinase 2 is a chikungunya virus host factor co-localized with the viral replication complex</article-title>. <source>Emerging microbes &#x0026; infections</source> <volume>4</volume>: <fpage>1</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c82"><label>82.</label><mixed-citation publication-type="journal"><string-name><surname>Cai</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Zhan</surname> <given-names>FX</given-names></string-name>, <string-name><surname>Kong</surname> <given-names>XN</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>SZ</given-names></string-name>, <string-name><surname>Cui</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Q</given-names></string-name>, <year>2018</year>. <article-title>RING domain of zinc finger protein like 1 is essential for cell proliferation in endometrial cancer cell line RL95-2</article-title>. <source>Gene</source> <volume>677</volume>: <fpage>17</fpage>&#x2013;<lpage>23</lpage>.</mixed-citation></ref>
<ref id="c83"><label>83.</label><mixed-citation publication-type="journal"><string-name><surname>Kurd</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ben-Chetrit</surname> <given-names>E</given-names></string-name>, <string-name><surname>Karameh</surname> <given-names>H</given-names></string-name>, <string-name><surname>Bar-Meir</surname> <given-names>M</given-names></string-name>, <year>2020</year>. <article-title>Compassionate Use of Opaganib For Patients with Severe COVID-19</article-title>. <source>medRxiv</source>.</mixed-citation></ref>
<ref id="c84"><label>84.</label><mixed-citation publication-type="journal"><string-name><surname>Shamsi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mohammad</surname> <given-names>T</given-names></string-name>, <string-name><surname>Anwar</surname> <given-names>S</given-names></string-name>, <string-name><surname>AlAjmi</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Hussain</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rehman</surname> <given-names>M</given-names></string-name>, <string-name><surname>Islam</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hassan</surname> <given-names>M</given-names></string-name>, <year>2020</year>. <article-title>Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy</article-title>. <source>Bioscience Reports</source> <volume>40</volume>.</mixed-citation></ref>
<ref id="c85"><label>85.</label><mixed-citation publication-type="journal"><string-name><surname>Okamoto</surname> <given-names>M</given-names></string-name>, <string-name><surname>Toyama</surname> <given-names>M</given-names></string-name>, <string-name><surname>Baba</surname> <given-names>M</given-names></string-name>, <year>2020</year>. <article-title>The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro</article-title>. <source>Antiviral Research</source> <volume>182</volume>: <fpage>104902</fpage>.</mixed-citation></ref>
<ref id="c86"><label>86.</label><mixed-citation publication-type="journal"><collab>COVID-19 Clinical Research Coalition</collab>, <year>2020</year>. <article-title>Global coalition to accelerate COVID-19 clinical research in resource-limited settings</article-title>. <source>Lancet</source> <volume>395</volume>: <fpage>1322</fpage>&#x2013;<lpage>1325</lpage>.</mixed-citation></ref>
<ref id="c87"><label>87.</label><mixed-citation publication-type="other"><string-name><surname>Gendrot</surname> <given-names>M</given-names></string-name>, <string-name><surname>Andreani</surname> <given-names>J</given-names></string-name>, <string-name><surname>Jardot</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hutter</surname> <given-names>S</given-names></string-name>, <string-name><surname>Boxberger</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mosnier</surname> <given-names>J</given-names></string-name>, <string-name><surname>Le Bideau</surname> <given-names>M</given-names></string-name>, <string-name><surname>Duflot</surname> <given-names>I</given-names></string-name>, <string-name><surname>Fonta</surname> <given-names>I</given-names></string-name>, <string-name><surname>Rolland</surname> <given-names>C</given-names></string-name>, <source>In vitro antiviral activity of doxycycline against SARS-CoV-2</source>.</mixed-citation></ref>
<ref id="c88"><label>88.</label><mixed-citation publication-type="journal"><string-name><surname>Cai</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>B</given-names></string-name>, <string-name><surname>Yao</surname> <given-names>W</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Zeng</surname> <given-names>M</given-names></string-name>, <year>2014</year>. <article-title>Prevalence, genetic drift of haemagglutinin, and antiviral resistance of influenza A/H3N2 viruses circulating in Shanghai in children during 2009-2012</article-title>. <source>J Med Virol</source> <volume>86</volume>: <fpage>1026</fpage>&#x2013;<lpage>33</lpage>.</mixed-citation></ref>
<ref id="c89"><label>89.</label><mixed-citation publication-type="journal"><string-name><surname>Rothan</surname> <given-names>HA</given-names></string-name>, <string-name><surname>Mohamed</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Paydar</surname> <given-names>M</given-names></string-name>, <string-name><surname>Abd Rahman</surname> <given-names>N</given-names></string-name>, <string-name><surname>Yusof</surname> <given-names>R</given-names></string-name>, <year>2014</year>. <article-title>Inhibitory effect of doxycycline against dengue virus replication in vitro</article-title>. <source>Archives of virology</source> <volume>159</volume>: <fpage>711</fpage>&#x2013;<lpage>718</lpage>.</mixed-citation></ref>
<ref id="c90"><label>90.</label><mixed-citation publication-type="journal"><string-name><surname>Fredeking</surname> <given-names>TM</given-names></string-name>, <string-name><surname>Zavala-Castro</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Gonz&#x00E1;lez-Mart&#x00ED;nez</surname> <given-names>P</given-names></string-name>, <string-name><surname>Moguel-Rodr&#x00ED;guez</surname> <given-names>WC</given-names></string-name> <string-name><surname>Sanchez</surname> <given-names>E J</given-names></string-name> <string-name><surname>Foster</surname> <given-names>MA</given-names></string-name> <string-name><surname>Diaz-Quijano</surname> <given-names>F</given-names></string-name>, <year>2015</year>. <article-title>Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels</article-title>. <source>Recent patents on anti-infective drug discovery</source> <volume>10</volume>: <fpage>51</fpage>&#x2013;<lpage>58</lpage>.</mixed-citation></ref>
<ref id="c91"><label>91.</label><mixed-citation publication-type="journal"><string-name><surname>Barretto</surname> <given-names>N</given-names></string-name>, <string-name><surname>Jukneliene</surname> <given-names>D</given-names></string-name>, <string-name><surname>Ratia</surname> <given-names>K</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Mesecar</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Baker</surname> <given-names>SC</given-names></string-name>, <year>2005</year>. <article-title>The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity</article-title>. <source>Journal of virology</source> <volume>79</volume>: <fpage>15189</fpage>&#x2013;<lpage>15198</lpage>.</mixed-citation></ref>
<ref id="c92"><label>92.</label><mixed-citation publication-type="journal"><string-name><surname>Cai</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>W</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>W</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>W</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sander</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Dan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>L</given-names></string-name>, <string-name><surname>Qin</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yan</surname> <given-names>G</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Liang</surname> <given-names>J</given-names></string-name>, <year>2020</year>. <article-title>Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer</article-title>. <source>Oncogene</source> <volume>39</volume>: <fpage>5995</fpage>&#x2013;<lpage>6008</lpage>.</mixed-citation></ref>
<ref id="c93"><label>93.</label><mixed-citation publication-type="journal"><string-name><surname>Hashim</surname> <given-names>HA</given-names></string-name>, <string-name><surname>Maulood</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Rasheed</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Fatak</surname> <given-names>DF</given-names></string-name>, <string-name><surname>Kabah</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Abdulamir</surname> <given-names>AS</given-names></string-name>, <year>2020</year>. <article-title>Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq</article-title>. <source>medRxiv</source>.</mixed-citation></ref>
<ref id="c94"><label>94.</label><mixed-citation publication-type="journal"><string-name><surname>Stebbing</surname> <given-names>J</given-names></string-name>, <string-name><surname>Krishnan</surname> <given-names>V</given-names></string-name>, <string-name><surname>de Bono</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ottaviani</surname> <given-names>S</given-names></string-name>, <string-name><surname>Casalini</surname> <given-names>G</given-names></string-name>, <string-name><surname>Richardson</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Monteil</surname> <given-names>V</given-names></string-name>, <string-name><surname>Lauschke</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Mirazimi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Youhanna</surname> <given-names>S</given-names></string-name>, <year>2020</year>. <article-title>Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</article-title>. <source>EMBO Molecular Medicine</source>.</mixed-citation></ref>
<ref id="c95"><label>95.</label><mixed-citation publication-type="journal"><string-name><surname>Bekerman</surname> <given-names>E</given-names></string-name>, <string-name><surname>Neveu</surname> <given-names>G</given-names></string-name>, <string-name><surname>Shulla</surname> <given-names>A</given-names></string-name>, <string-name><surname>Brannan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Pu</surname> <given-names>S-Y</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Xiao</surname> <given-names>F</given-names></string-name>, <string-name><surname>Barouch-Bentov</surname> <given-names>R</given-names></string-name>, <string-name><surname>Bakken</surname> <given-names>RR</given-names></string-name>, <string-name><surname>Mateo</surname> <given-names>R</given-names></string-name>, <year>2017</year>. <article-title>Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</article-title>. <source>The Journal of clinical investigation</source> <volume>127</volume>: <fpage>1338</fpage>&#x2013;<lpage>1352</lpage>.</mixed-citation></ref>
<ref id="c96"><label>96.</label><mixed-citation publication-type="journal"><string-name><surname>Cantini</surname> <given-names>F</given-names></string-name>, <string-name><surname>Niccoli</surname> <given-names>L</given-names></string-name>, <string-name><surname>Nannini</surname> <given-names>C</given-names></string-name>, <string-name><surname>Matarrese</surname> <given-names>D</given-names></string-name>, <string-name><surname>Di Natale</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Lotti</surname> <given-names>P</given-names></string-name>, <string-name><surname>Aquilini</surname> <given-names>D</given-names></string-name>, <string-name><surname>Landini</surname> <given-names>G</given-names></string-name>, <string-name><surname>Cimolato</surname> <given-names>B</given-names></string-name>, <string-name><surname>Di Pietro</surname> <given-names>MA</given-names></string-name>, <year>2020</year>. <article-title>Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study</article-title>. <source>Journal of Infection</source> <volume>81</volume>: <fpage>647</fpage>&#x2013;<lpage>679</lpage>.</mixed-citation></ref>
<ref id="c97"><label>97.</label><mixed-citation publication-type="journal"><string-name><surname>Titanji</surname> <given-names>BK</given-names></string-name>, <string-name><surname>Farley</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Mehta</surname> <given-names>A</given-names></string-name>, <string-name><surname>Connor-Schuler</surname> <given-names>R</given-names></string-name>, <string-name><surname>Moanna</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cribbs</surname> <given-names>SK</given-names></string-name>, <string-name><surname>O&#x2019;Shea</surname> <given-names>J</given-names></string-name>, <string-name><surname>DeSilva</surname> <given-names>K</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>B</given-names></string-name>, <string-name><surname>Edwards</surname> <given-names>A</given-names></string-name>, <year>2020</year>. <article-title>Use of baricitinib in patients with moderate and severe COVID-19</article-title>. <source>Clinical Infectious Diseases</source>.</mixed-citation></ref>
<ref id="c98"><label>98.</label><mixed-citation publication-type="website"><collab>PRNewswire, Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen</collab> Available at: <ext-link ext-link-type="uri" xlink:href="https://www.prnewswire.com/news-releases/baricitinib-has-significant-effect-on-recovery-time-most-impactful-in-covid-19-patients-requiring-oxygen-301148840.html">https://www.prnewswire.com/news-releases/baricitinib-has-significant-effect-on-recovery-time-most-impactful-in-covid-19-patients-requiring-oxygen-301148840.html</ext-link>. Accessed <date-in-citation content-type="access-date">23 Oct, 2020</date-in-citation>.</mixed-citation></ref>
<ref id="c99"><label>99.</label><mixed-citation publication-type="journal"><string-name><surname>Sheahan</surname> <given-names>TP</given-names></string-name>, <string-name><surname>Sims</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>S</given-names></string-name>, <string-name><surname>Graham</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Pruijssers</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Agostini</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Leist</surname> <given-names>SR</given-names></string-name>, <string-name><surname>Sch&#x00E4;fer</surname> <given-names>A</given-names></string-name>, <string-name><surname>Dinnon</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Stevens</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Chappell</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Hughes</surname> <given-names>TM</given-names></string-name>, <string-name><surname>George</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Hill</surname> <given-names>CS</given-names></string-name>, <string-name><surname>Montgomery</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Brown</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Bluemling</surname> <given-names>GR</given-names></string-name>, <string-name><surname>Natchus</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Saindane</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kolykhalov</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Painter</surname> <given-names>G</given-names></string-name>, <string-name><surname>Harcourt</surname> <given-names>J</given-names></string-name>, <string-name><surname>Tamin</surname> <given-names>A</given-names></string-name>, <string-name><surname>Thornburg</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Swanstrom</surname> <given-names>R</given-names></string-name>, <string-name><surname>Denison</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Baric</surname> <given-names>RS</given-names></string-name>, <year>2020</year>. <article-title>An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice</article-title>. <source>Science Translational Medicine</source> <volume>12</volume>: <fpage>eabb5883</fpage>.</mixed-citation></ref>
<ref id="c100"><label>100.</label><mixed-citation publication-type="journal"><string-name><surname>Snow</surname> <given-names>RW</given-names></string-name>, <string-name><surname>Korenromp</surname> <given-names>EL</given-names></string-name>, <string-name><surname>Gouws</surname> <given-names>E</given-names></string-name>, <year>2004</year>. <article-title>Pediatric mortality in Africa: Plasmodium falciparum malaria as a cause or risk?</article-title> <source>The American journal of tropical medicine and hygiene</source> <volume>71</volume>: <fpage>16</fpage>&#x2013;<lpage>24</lpage>.</mixed-citation></ref>
<ref id="c101"><label>101.</label><mixed-citation publication-type="website"><collab>WHO</collab>, <year>2020</year>. <source>The Access to COVID-19 Tools (ACT) Accelerator</source>. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/initiatives/act-accelerator">https://www.who.int/initiatives/act-accelerator</ext-link>. Accessed <date-in-citation content-type="access-date">19 Nov 2020, 2020</date-in-citation>.</mixed-citation></ref>
<ref id="c102"><label>102.</label><mixed-citation publication-type="website"><collab>United States National Institute of Health</collab>, <year>2020</year>. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.nih.gov/research-training/medical-research-initiatives/activ">https://www.nih.gov/research-training/medical-research-initiatives/activ</ext-link>. Accessed <date-in-citation content-type="access-date">Nov 20, 2020</date-in-citation>.</mixed-citation></ref>
<ref id="c103"><label>103.</label><mixed-citation publication-type="journal"><string-name><surname>Vamathevan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Clark</surname> <given-names>D</given-names></string-name>, <string-name><surname>Czodrowski</surname> <given-names>P</given-names></string-name>, <string-name><surname>Dunham</surname> <given-names>I</given-names></string-name>, <string-name><surname>Ferran</surname> <given-names>E</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>G</given-names></string-name>, <string-name><surname>Li</surname> <given-names>B</given-names></string-name>, <string-name><surname>Madabhushi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Shah</surname> <given-names>P</given-names></string-name>, <string-name><surname>Spitzer</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>S</given-names></string-name>, <year>2019</year>. <article-title>Applications of machine learning in drug discovery and development</article-title>. <source>Nature Reviews Drug Discovery</source> <volume>18</volume>: <fpage>463</fpage>&#x2013;<lpage>477</lpage>.</mixed-citation></ref>
<ref id="c104"><label>104.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <year>2020</year>. <article-title>Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study</article-title>. <source>Journal of Chemical Information and Modeling</source> <volume>60</volume>: <fpage>3277</fpage>&#x2013;<lpage>3286</lpage>.</mixed-citation></ref>
<ref id="c105"><label>105.</label><mixed-citation publication-type="journal"><string-name><surname>Gordon</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Jang</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Bouhaddou</surname> <given-names>M</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Obernier</surname> <given-names>K</given-names></string-name>, <string-name><surname>White</surname> <given-names>KM</given-names></string-name>, <string-name><surname>O&#x2019;Meara</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Rezelj</surname> <given-names>VV</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>JZ</given-names></string-name>, <string-name><surname>Swaney</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Tummino</surname> <given-names>TA</given-names></string-name>, <string-name><surname>Huettenhain</surname> <given-names>R</given-names></string-name>, <string-name><surname>Kaake</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Richards</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Tutuncuoglu</surname> <given-names>B</given-names></string-name>, <string-name><surname>Foussard</surname> <given-names>H</given-names></string-name>, <string-name><surname>Batra</surname> <given-names>J</given-names></string-name>, <string-name><surname>Haas</surname> <given-names>K</given-names></string-name>, <string-name><surname>Modak</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>M</given-names></string-name>, <string-name><surname>Haas</surname> <given-names>P</given-names></string-name>, <string-name><surname>Polacco</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Braberg</surname> <given-names>H</given-names></string-name>, <string-name><surname>Fabius</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Eckhardt</surname> <given-names>M</given-names></string-name>, <string-name><surname>Soucheray</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bennett</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Cakir</surname> <given-names>M</given-names></string-name>, <string-name><surname>McGregor</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Meyer</surname> <given-names>B</given-names></string-name>, <string-name><surname>Roesch</surname> <given-names>F</given-names></string-name>, <string-name><surname>Vallet</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mac Kain</surname> <given-names>A</given-names></string-name>, <string-name><surname>Miorin</surname> <given-names>L</given-names></string-name>, <string-name><surname>Moreno</surname> <given-names>E</given-names></string-name>, <string-name><surname>Naing</surname> <given-names>ZZC</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Peng</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>W</given-names></string-name>, <string-name><surname>Kirby</surname> <given-names>IT</given-names></string-name>, <string-name><surname>Melnyk</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Chorba</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Lou</surname> <given-names>K</given-names></string-name>, <string-name><surname>Dai</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Barrio-Hernandez</surname> <given-names>I</given-names></string-name>, <string-name><surname>Memon</surname> <given-names>D</given-names></string-name>, <string-name><surname>Hernandez-Armenta</surname> <given-names>C</given-names></string-name>, <string-name><surname>Lyu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mathy</surname> <given-names>CJP</given-names></string-name>, <string-name><surname>Perica</surname> <given-names>T</given-names></string-name>, <string-name><surname>Pilla</surname> <given-names>KB</given-names></string-name>, <string-name><surname>Ganesan</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Saltzberg</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Rakesh</surname> <given-names>R</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Rosenthal</surname> <given-names>SB</given-names></string-name>, <string-name><surname>Calviello</surname> <given-names>L</given-names></string-name>, <string-name><surname>Venkataramanan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Liboy-Lugo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>X-P</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wankowicz</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Bohn</surname> <given-names>M</given-names></string-name>, <string-name><surname>Safari</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ugur</surname> <given-names>FS</given-names></string-name>, <string-name><surname>Koh</surname> <given-names>C</given-names></string-name>, <string-name><surname>Savar</surname> <given-names>NS</given-names></string-name>, <string-name><surname>Tran</surname> <given-names>QD</given-names></string-name>, <string-name><surname>Shengjuler</surname> <given-names>D</given-names></string-name>, <string-name><surname>Fletcher</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>O&#x2019;Neal</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Cai</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Chang</surname> <given-names>JCJ</given-names></string-name>, <string-name><surname>Broadhurst</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Klippsten</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sharp</surname> <given-names>PP</given-names></string-name>, <string-name><surname>Wenzell</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Kuzuoglu</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>H-Y</given-names></string-name>, <string-name><surname>Trenker</surname> <given-names>R</given-names></string-name>, <string-name><surname>Young</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Cavero</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Hiatt</surname> <given-names>J</given-names></string-name>, <string-name><surname>Roth</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Rathore</surname> <given-names>U</given-names></string-name>, <string-name><surname>Subramanian</surname> <given-names>A</given-names></string-name>, <string-name><surname>Noack</surname> <given-names>J</given-names></string-name>, <string-name><surname>Hubert</surname> <given-names>M</given-names></string-name>, <string-name><surname>Stroud</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Frankel</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Rosenberg</surname> <given-names>OS</given-names></string-name>, <string-name><surname>Verba</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Agard</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Ott</surname> <given-names>M</given-names></string-name>, <string-name><surname>Emerman</surname> <given-names>M</given-names></string-name>, <string-name><surname>Jura</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal>, <year>2020</year>. <article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title>. <source>Nature</source>.</mixed-citation></ref>
<ref id="c106"><label>106.</label><mixed-citation publication-type="journal"><string-name><surname>Janes</surname> <given-names>J</given-names></string-name>, <string-name><surname>Young</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>E</given-names></string-name>, <string-name><surname>Rogers</surname> <given-names>NH</given-names></string-name>, <string-name><surname>Burgstaller-Muehlbacher</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hughes</surname> <given-names>LD</given-names></string-name>, <string-name><surname>Love</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Hull</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Kuhen</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Woods</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Joseph</surname> <given-names>SB</given-names></string-name>, <string-name><surname>Petrassi</surname> <given-names>HM</given-names></string-name>, <string-name><surname>McNamara</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Tremblay</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Su</surname> <given-names>AI</given-names></string-name>, <string-name><surname>Schultz</surname> <given-names>PG</given-names></string-name>, <string-name><surname>Chatterjee</surname> <given-names>AK</given-names></string-name>, <year>2018</year>. <article-title>The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>115</volume>: <fpage>10750</fpage>&#x2013;<lpage>10755</lpage>.</mixed-citation></ref>
<ref id="c107"><label>107.</label><mixed-citation publication-type="journal"><string-name><surname>Riva</surname> <given-names>L</given-names></string-name>, <string-name><surname>Yuan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Yin</surname> <given-names>X</given-names></string-name>, <string-name><surname>Martin-Sancho</surname> <given-names>L</given-names></string-name>, <string-name><surname>Matsunaga</surname> <given-names>N</given-names></string-name>, <string-name><surname>Pache</surname> <given-names>L</given-names></string-name>, <string-name><surname>Burgstaller-Muehlbacher</surname> <given-names>S</given-names></string-name>, <string-name><surname>De Jesus</surname> <given-names>PD</given-names></string-name>, <string-name><surname>Teriete</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hull</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Chang</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>JF-W</given-names></string-name>, <string-name><surname>Cao</surname> <given-names>J</given-names></string-name>, <string-name><given-names>Poon</given-names> <surname>VK-M</surname></string-name>, <string-name><surname>Herbert</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nguyen</surname> <given-names>T-TH</given-names></string-name>, <string-name><surname>Rubanov</surname> <given-names>A</given-names></string-name>, <string-name><surname>Pu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Nguyen</surname> <given-names>C</given-names></string-name>, <string-name><surname>Choi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rathnasinghe</surname> <given-names>R</given-names></string-name>, <string-name><surname>Schotsaert</surname> <given-names>M</given-names></string-name>, <string-name><surname>Miorin</surname> <given-names>L</given-names></string-name>, <string-name><surname>Dejosez</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zwaka</surname> <given-names>TP</given-names></string-name>, <string-name><surname>Sit</surname> <given-names>K-Y</given-names></string-name>, <string-name><surname>Martinez-Sobrido</surname> <given-names>L</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>W-C</given-names></string-name>, <string-name><surname>White</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Chapman</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Lendy</surname> <given-names>EK</given-names></string-name>, <string-name><surname>Glynne</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Albrecht</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ruppin</surname> <given-names>E</given-names></string-name>, <string-name><surname>Mesecar</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Benner</surname> <given-names>C</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>R</given-names></string-name>, <string-name><surname>Schultz</surname> <given-names>PG</given-names></string-name>, <string-name><surname>Su</surname> <given-names>AI</given-names></string-name>, <string-name><surname>Garc&#x00ED;a-Sastre</surname> <given-names>A</given-names></string-name>, <string-name><surname>Chatterjee</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Yuen</surname> <given-names>K-Y</given-names></string-name>, <string-name><surname>Chanda</surname> <given-names>SK</given-names></string-name>, <year>2020</year>. <article-title>Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing</article-title>. <source>Nature</source>.</mixed-citation></ref>
<ref id="c108"><label>108.</label><mixed-citation publication-type="journal"><string-name><surname>Maeda</surname> <given-names>K</given-names></string-name>, <string-name><surname>Das</surname> <given-names>D</given-names></string-name>, <string-name><surname>Kobayakawa</surname> <given-names>T</given-names></string-name>, <string-name><surname>Tamamura</surname> <given-names>H</given-names></string-name>, <string-name><surname>Takeuchi</surname> <given-names>H</given-names></string-name>, <year>2019</year>. <article-title>Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication</article-title>. <source>Curr Top Med Chem</source> <volume>19</volume>: <fpage>1621</fpage>&#x2013;<lpage>1649</lpage>.</mixed-citation></ref>
<ref id="c109"><label>109.</label><mixed-citation publication-type="journal"><string-name><surname>Vilarinho</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lifton</surname> <given-names>RP</given-names></string-name>, <year>2016</year>. <article-title>Pioneering a global cure for chronic hepatitis C virus infection</article-title>. <source>Cell</source> <volume>167</volume>: <fpage>12</fpage>&#x2013;<lpage>15</lpage>.</mixed-citation></ref>
<ref id="c110"><label>110.</label><mixed-citation publication-type="journal"><year>2017</year>. <article-title>Rationalizing combination therapies</article-title>. <source>Nature Medicine</source> <volume>23</volume>: <fpage>1113</fpage>&#x2013;<lpage>1113</lpage>.</mixed-citation></ref>
<ref id="c111"><label>111.</label><mixed-citation publication-type="journal"><string-name><surname>Phougat</surname> <given-names>N</given-names></string-name>, <string-name><surname>Khatri</surname> <given-names>S</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>A</given-names></string-name>, <string-name><surname>Dangi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>M</given-names></string-name>, <string-name><surname>Dabur</surname> <given-names>R</given-names></string-name>, <string-name><surname>Chhillar</surname> <given-names>AK</given-names></string-name>, <year>2014</year>. <article-title>Combination therapy: the propitious rationale for drug development</article-title>. <source>Comb Chem High Throughput Screen</source> <volume>17</volume>: <fpage>53</fpage>&#x2013;<lpage>67</lpage>.</mixed-citation></ref>
<ref id="c112"><label>112.</label><mixed-citation publication-type="journal"><string-name><surname>Bobrowski</surname> <given-names>T</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>L</given-names></string-name>, <string-name><surname>Eastman</surname> <given-names>RT</given-names></string-name>, <string-name><surname>Itkin</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Shinn</surname> <given-names>P</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>C</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>W</given-names></string-name>, <string-name><surname>Michael</surname> <given-names>S</given-names></string-name>, <string-name><surname>Simeonov</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hall</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Zakharov</surname> <given-names>AV</given-names></string-name>, <string-name><surname>Muratov</surname> <given-names>EN</given-names></string-name>, <year>2020</year>. <article-title>Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro</article-title>. <source>bioRxiv</source>.</mixed-citation></ref>
<ref id="c113"><label>113.</label><mixed-citation publication-type="journal"><string-name><surname>McNamara</surname> <given-names>LA</given-names></string-name>, <string-name><surname>MacNeil</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Cohn</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Stephens</surname> <given-names>DS</given-names></string-name>, <year>2018</year>. <article-title>Mass chemoprophylaxis for control of outbreaks of meningococcal disease</article-title>. <source>Lancet Infect Dis</source> <volume>18</volume>: <fpage>e272</fpage>&#x2013;<lpage>e281</lpage>.</mixed-citation></ref>
<ref id="c114"><label>114.</label><mixed-citation publication-type="journal"><string-name><surname>Hsiang</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Ntuku</surname> <given-names>H</given-names></string-name>, <string-name><surname>Roberts</surname> <given-names>KW</given-names></string-name>, <string-name><given-names>Dufour</given-names> <surname>M-SK</surname></string-name>, <string-name><surname>Whittemore</surname> <given-names>B</given-names></string-name>, <string-name><surname>Tambo</surname> <given-names>M</given-names></string-name>, <string-name><surname>McCreesh</surname> <given-names>P</given-names></string-name>, <string-name><surname>Medzihradsky</surname> <given-names>OF</given-names></string-name>, <string-name><surname>Prach</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Siloka</surname> <given-names>G</given-names></string-name>, <year>2020</year>. <article-title>Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial</article-title>. <source>The Lancet</source> <volume>395</volume>: <fpage>1361</fpage>&#x2013;<lpage>1373</lpage>.</mixed-citation></ref>
<ref id="c115"><label>115.</label><mixed-citation publication-type="journal"><string-name><surname>Mitja</surname> <given-names>O</given-names></string-name>, <string-name><surname>Corbacho-Monne</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ubals</surname> <given-names>M</given-names></string-name>, <string-name><surname>Tebe</surname> <given-names>C</given-names></string-name>, <string-name><surname>Penafiel</surname> <given-names>J</given-names></string-name>, <string-name><surname>Tobias</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ballana</surname> <given-names>E</given-names></string-name>, <string-name><surname>Alemany</surname> <given-names>A</given-names></string-name>, <string-name><surname>Riera-Marti</surname> <given-names>N</given-names></string-name>, <string-name><surname>Perez</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Suner</surname> <given-names>C</given-names></string-name>, <string-name><surname>Laporte</surname> <given-names>P</given-names></string-name>, <string-name><surname>Admella</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mitja</surname> <given-names>J</given-names></string-name>, <string-name><surname>Clua</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bertran</surname> <given-names>L</given-names></string-name>, <string-name><surname>Sarquella</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gavilan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ara</surname> <given-names>J</given-names></string-name>, <string-name><surname>Argimon</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Casabona</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cuatrecasas</surname> <given-names>G</given-names></string-name>, <string-name><surname>Canadas</surname> <given-names>P</given-names></string-name>, <string-name><surname>Elizalde-Torrent</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fabregat</surname> <given-names>R</given-names></string-name>, <string-name><surname>Farre</surname> <given-names>M</given-names></string-name>, <string-name><surname>Forcada</surname> <given-names>A</given-names></string-name>, <string-name><surname>Flores-Mateo</surname> <given-names>G</given-names></string-name>, <string-name><surname>Muntada</surname> <given-names>E</given-names></string-name>, <string-name><surname>Nadal</surname> <given-names>N</given-names></string-name>, <string-name><surname>Narejos</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gil-Ortega</surname> <given-names>AN</given-names></string-name>, <string-name><surname>Prat</surname> <given-names>N</given-names></string-name>, <string-name><surname>Puig</surname> <given-names>J</given-names></string-name>, <string-name><surname>Quinones</surname> <given-names>C</given-names></string-name>, <string-name><surname>Reyes-Urena</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ramirez-Viaplana</surname> <given-names>F</given-names></string-name>, <string-name><surname>Ruiz</surname> <given-names>L</given-names></string-name>, <string-name><surname>Riveira-Munoz</surname> <given-names>E</given-names></string-name>, <string-name><surname>Sierra</surname> <given-names>A</given-names></string-name>, <string-name><surname>Velasco</surname> <given-names>C</given-names></string-name>, <string-name><surname>Vivanco-Hidalgo</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Sentis</surname> <given-names>A</given-names></string-name>, C GB, <string-name><surname>Clotet</surname> <given-names>B</given-names></string-name>, <string-name><surname>Vall-Mayans</surname> <given-names>M</given-names></string-name>, <collab>GROUP BP-C-R</collab>, <year>2020</year>. <article-title>Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial</article-title>. <source>Clin Infect Dis</source>.</mixed-citation></ref>
<ref id="c116"><label>116.</label><mixed-citation publication-type="journal"><string-name><surname>Kulkarni</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fisk</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kostapanos</surname> <given-names>M</given-names></string-name>, <string-name><surname>Banham-Hall</surname> <given-names>E</given-names></string-name>, <string-name><surname>Bond</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hernan-Sancho</surname> <given-names>E</given-names></string-name>, <string-name><surname>Norton</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cheriyan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cope</surname> <given-names>A</given-names></string-name>, <string-name><surname>Galloway</surname> <given-names>J</given-names></string-name>, <string-name><surname>Hall</surname> <given-names>F</given-names></string-name>, <string-name><surname>Jayne</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wilkinson</surname> <given-names>IB</given-names></string-name>, <year>2020</year>. <article-title>Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients-mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 &#x2013; Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial</article-title>. <source>Trials</source> <volume>21</volume>.</mixed-citation></ref>
<ref id="c117"><label>117.</label><mixed-citation publication-type="journal"><string-name><surname>Lo Caputo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Corso</surname> <given-names>G</given-names></string-name>, <string-name><surname>Clerici</surname> <given-names>M</given-names></string-name>, <string-name><surname>Santantonio</surname> <given-names>TA</given-names></string-name>, <year>2020</year>. <article-title>Baricitinib: A chance to treat COVID-19?</article-title> <source>J Med Virol</source>.</mixed-citation></ref>
<ref id="c118"><label>118.</label><mixed-citation publication-type="other"><string-name><surname>Joshi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Giri</surname> <given-names>AP</given-names></string-name>, <string-name><surname>Kulkarni</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Verma</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chaudhary</surname> <given-names>D</given-names></string-name>, <string-name><surname>Deshmukh</surname> <given-names>N</given-names></string-name>, <string-name><surname>Chugh</surname> <given-names>A</given-names></string-name>, <year>2020</year>. <source>Rationale Based Selection and Prioritization of Antiviral Drugs for COVID-19 Management</source>.</mixed-citation></ref>
<ref id="c119"><label>119.</label><mixed-citation publication-type="journal"><string-name><surname>Xia</surname> <given-names>C</given-names></string-name>, <string-name><surname>Seo</surname> <given-names>Y-J</given-names></string-name>, <string-name><surname>Studstill</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Vijayan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wolf</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Hahm</surname> <given-names>B</given-names></string-name>, <year>2018</year>. <article-title>Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice</article-title>. <source>Antiviral research</source> <volume>158</volume>: <fpage>171</fpage>&#x2013;<lpage>177</lpage>.</mixed-citation></ref>
<ref id="c120"><label>120.</label><mixed-citation publication-type="website"><year>2020</year>. <source>Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19)</source>. (MARACOVID). Available at: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04441385?term=Maraviroc&#x0026;cond=Covid19&#x0026;draw=1&#x0026;rank=1">https://clinicaltrials.gov/ct2/show/NCT04441385?term=Maraviroc&#x0026;cond=Covid19&#x0026;draw=1&#x0026;rank=1</ext-link>. Accessed.</mixed-citation></ref>
<ref id="c121"><label>121.</label><mixed-citation publication-type="website"><year>2020</year>. <source>Maraviroc in Patients With Moderate and Severe COVID-19</source>. Available at: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04435522?term=Maraviroc&#x0026;cond=Covid19&#x0026;draw=1&#x0026;rank=3">https://clinicaltrials.gov/ct2/show/NCT04435522?term=Maraviroc&#x0026;cond=Covid19&#x0026;draw=1&#x0026;rank=3</ext-link>. Accessed.</mixed-citation></ref>
<ref id="c122"><label>122.</label><mixed-citation publication-type="journal"><string-name><surname>Gendrot</surname> <given-names>M</given-names></string-name>, <string-name><surname>Andreani</surname> <given-names>J</given-names></string-name>, <string-name><surname>Jardot</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hutter</surname> <given-names>S</given-names></string-name>, <string-name><surname>Delandre</surname> <given-names>O</given-names></string-name>, <string-name><surname>Boxberger</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mosnier</surname> <given-names>J</given-names></string-name>, <string-name><surname>Le Bideau</surname> <given-names>M</given-names></string-name>, <string-name><surname>Duflot</surname> <given-names>I</given-names></string-name>, <string-name><surname>Fonta</surname> <given-names>I</given-names></string-name>, <string-name><surname>Rolland</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bogreau</surname> <given-names>H</given-names></string-name>, <string-name><surname>La Scola</surname> <given-names>B</given-names></string-name>, <string-name><surname>Pradines</surname> <given-names>B</given-names></string-name>, <year>2020</year>. <article-title>In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2</article-title>. <source>Molecules</source> <volume>25</volume>.</mixed-citation></ref>
<ref id="c123"><label>123.</label><mixed-citation publication-type="journal"><string-name><surname>Phillips</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Gallagher</surname> <given-names>T</given-names></string-name>, <string-name><surname>Weiss</surname> <given-names>SR</given-names></string-name>, <year>2017</year>. <article-title>Neurovirulent murine coronavirus JHM. SD uses cellular zinc metalloproteases for virus entry and cell-cell fusion</article-title>. <source>Journal of virology</source> <volume>91</volume>.</mixed-citation></ref>
<ref id="c124"><label>124.</label><mixed-citation publication-type="journal"><string-name><surname>Vanlaere</surname> <given-names>I</given-names></string-name>, <string-name><surname>Libert</surname> <given-names>C</given-names></string-name>, <year>2009</year>. <article-title>Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock</article-title>. <source>Clinical microbiology reviews</source> <volume>22</volume>: <fpage>224</fpage>&#x2013;<lpage>239</lpage>.</mixed-citation></ref>
<ref id="c125"><label>125.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Tu</surname> <given-names>F</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>G</given-names></string-name>, <year>2012</year>. <article-title>Zinc-finger antiviral protein inhibits XMRV infection</article-title>. <source>PLoS One</source> <volume>7</volume>: <fpage>e39159</fpage>.</mixed-citation></ref>
<ref id="c126"><label>126.</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>P</given-names></string-name>, <string-name><surname>Zhong</surname> <given-names>W</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Li</surname> <given-names>M</given-names></string-name>, <string-name><surname>Li</surname> <given-names>X</given-names></string-name>, <year>2020</year>. <article-title>Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</article-title>. <source>Acta Pharmaceutica Sinica B</source>.</mixed-citation></ref>
<ref id="c127"><label>127.</label><mixed-citation publication-type="journal"><string-name><surname>Zhu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>G</given-names></string-name>, <string-name><surname>Lv</surname> <given-names>F</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Ji</surname> <given-names>X</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>YT</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>G</given-names></string-name>, <year>2011</year>. <article-title>Zinc-finger antiviral protein inhibits HIV-1 infection by selectively targeting multiply spliced viral mRNAs for degradation</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>108</volume>: <fpage>15834</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c128"><label>128.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname> <given-names>WM</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Jin</surname> <given-names>XL</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>HY</given-names></string-name>, <year>2007</year>. <article-title>[Malaria epidemic situation in Jiangsu Province in 2006]</article-title>. <source>Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi</source> <volume>25</volume>: <fpage>258</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c129"><label>129.</label><mixed-citation publication-type="journal"><string-name><surname>Cao</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zou</surname> <given-names>L</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>T</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>G</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>L</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Meng</surname> <given-names>F</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>N</given-names></string-name>, <year>2020</year>. <article-title>Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial</article-title>. <source>Journal of Allergy and Clinical Immunology</source>.</mixed-citation></ref>
<ref id="c130"><label>130.</label><mixed-citation publication-type="journal"><string-name><surname>Kalil</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Patterson</surname> <given-names>TF</given-names></string-name>, <string-name><surname>Mehta</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Tomashek</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Wolfe</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Ghazaryan</surname> <given-names>V</given-names></string-name>, <string-name><surname>Marconi</surname> <given-names>VC</given-names></string-name>, <string-name><surname>Ruiz-Palacios</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Hsieh</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kline</surname> <given-names>S</given-names></string-name>, <year>2020</year>. <article-title>Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19</article-title>. <source>New England Journal of Medicine</source>.</mixed-citation></ref>
<ref id="c131"><label>131.</label><mixed-citation publication-type="journal"><string-name><surname>Stebbing</surname> <given-names>J</given-names></string-name>, <string-name><surname>Phelan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Griffin</surname> <given-names>I</given-names></string-name>, <string-name><surname>Tucker</surname> <given-names>C</given-names></string-name>, <string-name><surname>Oechsle</surname> <given-names>O</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>D</given-names></string-name>, <string-name><surname>Richardson</surname> <given-names>P</given-names></string-name>, <year>2020</year>. <article-title>COVID-19: combining antiviral and anti-inflammatory treatments</article-title>. <source>The Lancet Infectious Diseases</source> <volume>20</volume>: <fpage>400</fpage>&#x2013;<lpage>402</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>